Flavor-modified proteins and food products containing them

Abstract

The present invention relates to modified MNEI proteins comprising an amino acid sequence having two or more amino acid deletions, insertions, replacements, or any combination thereof, from a reference MNEI protein, wherein the modified MNEI protein has at least one improved food-related property compared to the reference MNEI protein, and uses thereof in the food industry.

Description

Technical Field

[0001] The present invention relates to flavor-modified proteins, as well as formulations and food products containing them. The flavor-modified proteins can be provided in various formulations for animal feed and human consumption.

Background Art

[0002] [[ID=1,2]]

[0003]

[0004] Substitutes for sugar are becoming increasingly prominent due to increased disease awareness as a result of the overconsumption of sugar as a cause underlying metabolic syndrome. Known manifestations of metabolic syndrome are diabetes, obesity, dental caries, some types of cancer, and many additional diseases. The food industry is challenged to produce healthier and reduced-calorie foods to meet the demands of consumers and public policy authorities. As part of this, many countries have applied sugar taxes and warning labels. The food industry faces the challenge of making more natural and better foods and beverages that conform to consumer trends while providing the taste necessary for product success. Low-calorie sweetener ingredients are expanding the options for consumers seeking to reduce the calorie and sugar levels in their food, but these ingredients are limited by taste, stability, and versatility.To succeed in the global market, there is an urgent global need for healthy sweetener alternatives for food and beverage products that possess optimal sensory characteristics and good stability. Artificial high-intensity sweeteners (HIS), such as saccharin, aspartame, cyclamate, and acesulfame K, sucralose, neotame, and advantame, are used worldwide as low-calorie sweeteners for patients with sugar-related diseases such as diabetes, hyperlipidemia, and metabolic disorders. HIS have various side effects; for example, these zero-calorie sweeteners have been reported to interact with the microbiome, even to a lesser degree than sugar, and cause obesity and prediabetic conditions (Suez et al., 2014, Nature volume 514, pages 181-186). The American Heart Association has published advice on HIS, arguing that there is "a dearth of evidence for adverse health effects" (Johnson et al., 2018, Circulation, Vol. 138, No. 9). This advice places all natural (steviol glycoside and monk fruit) and artificial HIS under the same scrutiny. Furthermore, low-intensity sweeteners (LIS), i.e., rare sugars and polyols (e.g., xylitol, mannitol, allulose), are expensive, not fully digested by the human body, and their use is limited to avoid bloating, diarrhea, and other harmful gastrointestinal effects. Therefore, currently, there are no good sugar alternatives that allow for a significant (more than 30%) reduction in sugar while fully addressing taste, health, cost, and product suitability.

[0005] Sweet proteins (SPs), unlike sucrose, do not induce an insulin response and therefore have no glycemic index, offering the potential to replace HIS by providing a naturally delicious, low-calorie sweetener (Weihrauch 2001 and Cohen 2001). SPs are found in tropical fruits and are 700 to 3,000 times sweeter than sugar. These healthy sweeteners bind to sweet receptors like sugar but are digested as proteins. They have a glycemic index of zero, contain approximately 0 calories, and are expected to have no adverse effects on health or the microbiome. Thaumatin is currently the only sweet protein globally approved on the market. Due to its high price, limited supply, and suboptimal sensory profile, SPs are generally not used as a significant (over 30%) sugar reduction solution. Apart from thaumatin, SPs have not entered the mass food market due to their cost, limited supply, low stability, short shelf life, especially in a fatty environment, and aftertaste. Therefore, it is necessary to develop compositions and formulations that overcome one or more of the aforementioned problems.

[0006] British Patent No. 2123672 describes a mildly acidic polysaccharide gum incorporated into various beverages, mouthwashes, or as a pharmaceutical base, together with sweet proteins such as thaumatin and monellin, and optionally with edible acids or bulking agents.

[0007] International Publication No. 8402450 describes the application of thaumatin or monellin to the surface of a chewing gum composition containing a gum base, sweeteners, and flavorings.

[0008] International Publication No. 2019 / 215730 discloses a modified protein with improved food-related properties. [Overview of the project]

[0009] In some aspects, the disclosure provides a modified version of a single-chain monellin (MNEI) protein comprising an amino acid sequence having two or more amino acid deletions, insertions, substitutions, or any combination thereof from an MNEI reference protein, wherein the modified MNEI protein has at least one improved food-related property compared to the reference MNEI protein.

[0010] According to several other embodiments, the disclosure provides a food product comprising a modified MNEI protein, which comprises an amino acid sequence having two or more amino acid deletions, insertions, substitutions, or any combination thereof from an MNEI reference protein, wherein the modified MNEI protein has at least one improved food-related property compared to the reference MNEI protein. According to several embodiments, the modified protein comprises at least three amino acid deletions, insertions, substitutions, or any combination thereof from a reference MNEI protein.

[0011] According to some embodiments, the deletion, insertion, substitution, or any combination thereof of two or more amino acids is located on the surface of the reference MNEI protein or in the core of the reference MNEI protein. According to some embodiments, the deletion, insertion, substitution, or any combination thereof of two or more amino acids is located within the modified MNEI loop (also called the "linker region") and the beta-chain edge. According to some embodiments, the deletion, insertion, substitution, or any combination thereof of two or more amino acids is located within the modified MNEI loop and the beta-chain edge spanning 46 to 56 residues.

[0012] According to some embodiments, the stabilization of the loop region is achieved by (i) adding at least one hydrogen bond, (ii) extending the beta chain that holds the loop region, (iii) reducing the relative Debye-Waller factor in the loop region, or (iv) stabilizing the loop region by at least one of any combination thereof, which is a deletion, substitution, replacement, grafting, or any combination thereof of the amino acid. According to some embodiments, the stabilization is associated with (i) reduced aggregation, (ii) increased melting temperature, (iii) increased shelf-life stability, or (iv) at least one of any combination thereof.

[0013] According to some embodiments, the modified MNEI protein has an energy of less than -182, expressed in Rosetta Energy Units (REU).

[0014] According to some embodiments, at least one food-related property is at least one of sweetness, sweetness dynamics, masking effect, taste enhancement, off-flavor, or any combination thereof. According to some embodiments, the modified MNEI protein has a sweetness level that is at least 1.5 times higher than that of the reference MNEI protein.

[0015] According to several embodiments, the modified MNEI protein is characterized by at least one of the following compared to the reference MNEI protein: (1) increased thermal stability, (2) increased pH stability, (3) increased solubility, (4) reduced binding to hydrophobic regions, (5) high-pressure stability, (6) increased shelf-life stability, and any combination thereof.

[0016] According to some embodiments, the modified MNEI protein comprises an amino acid sequence, or a fragment or variant thereof, selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21.

[0017] According to some embodiments, the reference MNEI protein has the sequence described in SEQ ID NO: 45.

[0018] According to some embodiments, modified MNEI proteins or any combination thereof are used in the preparation of oral delivery products.

[0019] According to some embodiments, the product is a food product, a nutritional supplement product, or a drug.

[0020] According to some embodiments, modified MNEI proteins or any combination thereof are used as flavor modifiers or flavor enhancers.

[0021] According to some embodiments, the modified MNEI protein is used as a sweetener.

[0022] In some embodiments, the present disclosure provides food products containing the modified protein of the present invention.

[0023] According to some embodiments, the food product comprises at least one food ingredient. According to some embodiments, the food ingredient is at least one of an artificial flavorant, a food additive, an edible dye, a preservative, or a sugar additive. According to some embodiments, the food ingredient is selected from the group consisting of stevia, sucrose, agave nectar, brown rice syrup, coconut sugar, honey, maple syrup, molasses, lakanka, sugar alcohol, rare sugar, aspartame, sucralose, acesulfame potassium, saccharin, neotame, advantame, and dietary fiber.

[0024] According to some embodiments, the stevia is rebaudioside or steviol glycoside. According to some embodiments, the rebaudioside is RebM.

[0025] According to some embodiments, there is a synergistic effect between RebM and the modified MNEI protein of the present invention.

[0026] According to some aspects, the present disclosure provides a sweet composition comprising the modified MNEI protein of the present invention. According to some embodiments, the present disclosure provides an ingestible composition comprising the sweet composition. According to some embodiments, the ingestible composition has a low glycemic effect and is in the form of a liquid or solid food product.

[0027] According to some aspects, the present invention provides specific food and beverage formulations having improved food or beverage-related properties.

[0028] According to some aspects, the present disclosure provides a food or beverage formulation comprising one or more modified single-chain monellin (MNEI) proteins in the range of about 0.2 mg to about 30 mg per 100 gr or 100 ml. According to some embodiments, the range is about 0.4 mg to about 10 mg per 100 gr or 100 ml.

[0029] According to some embodiments, the formulation has a pH in the range of about 2 to about 8.5.

[0030] According to some embodiments, the modified MNEI protein contains an amino acid sequence that has 40% to 99% identity with a reference MNEI protein containing the amino acid sequence described in SEQ ID NO: 45.

[0031] According to some embodiments, the modified MNEI comprises an amino acid sequence, or a fragment or variant thereof, selected from the group consisting of SEQ ID NOs: 1 to 27.

[0032] According to some embodiments, the modified MNEI protein is a digestible protein.

[0033] According to some embodiments, the present invention provides a food or beverage composition formulated for consumption by human subjects, the composition comprising the formulation.

[0034] According to some embodiments, the beverage composition is selected from the group consisting of carbonated soft drinks, non-carbonated soft drinks, fountain beverages, frozen ready-to-drink beverages, coffee beverages, tea beverages, milk beverages, fruit beverages, flavored water, fortified water, sports drinks, energy drinks, isotonic drinks, low-calorie drinks, and alcoholic beverages.

[0035] According to some embodiments, the food composition is selected from the group consisting of baked goods, cookies, biscuits, baking mixes, cereals, confectionery, candies, toffee, chewing gum, dairy products, yogurt, flavored yogurt, soy sauce and other soy-based products, non-dairy products, salad dressings, ketchup, mayonnaise, vinegar, frozen desserts, meat products, fish products, bottled and canned foods, table sweeteners, chocolate, fruits, dried fruits, and vegetables.

[0036] According to some embodiments, the composition has at least one improved food or beverage-related property compared to a food or beverage composition having a reference MNEI protein.

[0037] According to some embodiments, at least one improved food or beverage-related property is selected from the group consisting of an improved sweetness profile, a shortened sweet aftertaste, an improved sweetness level, improved sweetness dynamics, increased thermal stability, high-pressure stability, increased pH stability, reduced binding to the hydrophobic region, improved freeze-thaw stability, improved reconstitution after drying, increased solubility, a sensory profile closer to that of sugar, and increased shelf-life stability.

[0038] According to some embodiments, a food or beverage composition comprising at least one additional food ingredient.

[0039] According to some embodiments, the food ingredient is at least one of flavorings, food additives, food dyes, preservatives, or sweeteners.

[0040] According to some embodiments, the food ingredients are selected from the group consisting of stevia, sucrose, agave nectar, brown rice syrup, date sugar, honey, maple syrup, molasses, steviol glycoside, monk fruit, sugar alcohols, rare sugars, aspartame, sucralose, acesulfame potassium, saccharin, neotame, advantame, and dietary fiber.

[0041] According to some embodiments, the rare sugar is allulose or tagatose.

[0042] According to some embodiments, the food or beverage composition has a low blood glucose effect.

[0043] According to some embodiments, the carbonated soft drink is selected from the group consisting of cola, lemon-lime flavored sparkling beverage, orange-flavored sparkling beverage, grape-flavored sparkling beverage, grape-flavored sparkling beverage, raspberry-flavored sparkling beverage, strawberry-flavored sparkling beverage, pineapple-flavored sparkling beverage, ginger ale, root beer, and malt beverage.

[0044] According to some embodiments, non-carbonated soft drinks are selected from the group consisting of fruit juices, fruit-flavored juices, juice drinks, nectars, vegetable juices, vegetable-flavored juices, sports drinks, energy drinks, protein drinks, vitamin-fortified water, near-water drinks, coconut water, tea, coffee, cocoa drinks, milk-containing beverages, grain extract-containing beverages, and smoothies.

[0045] According to some embodiments, the formulation is used to prepare a product for oral delivery.

[0046] According to some embodiments, the product is a food product or beverage product, a nutritional supplement product, or a pharmaceutical product.

[0047] In some embodiments, the present disclosure provides food or beverage products comprising the formulation of the present invention.

[0048] In some embodiments, the present disclosure provides soft drink products containing the formulation that have little or no added sugar.

[0049] In some embodiments, the present disclosure provides dairy products containing the formulation with little or no added sugar. In some embodiments, the dairy product is yogurt or malabi.

[0050] According to some embodiments, the present disclosure provides a sauce product containing the formulation that is low in added sugar or sugar-free. According to some embodiments, the sauce is ketchup.

[0051] In some embodiments, the disclosure provides dried fruit containing the formulation with little or no added sugar. In some embodiments, the dried fruit is selected from the group consisting of cranberries, raisins, blueberries, prunes, cherries, apples, pineapples, watermelons, cantaloupes, figs, bananas, dates, currants, and apricots. In some embodiments, the dried fruit is fruit leather.

[0052] According to some embodiments, the present disclosure provides a gum product containing the formulation that is low in added sugar or sugar-free. According to some embodiments, the gum product is a chewing gum or a bubble gum product.

[0053] According to some embodiments, the disclosure provides a spread product containing the formulation that is low in added sugar or sugar-free. According to some embodiments, the spread product is peanut butter.

[0054] In some embodiments, the present disclosure provides syrup products containing the formulation with little or no added sugar.

[0055] To better understand the subject matter disclosed herein and to illustrate how it can actually be carried out, embodiments are described herein only as non-limiting examples, with reference to the accompanying drawings. [Brief explanation of the drawing]

[0056] [Figure 1] This is a histogram showing the relative sweetness of MNEI. The sweetness of the modified MNEI protein was evaluated on a 6°Bx scale based on its potency at a 1:4000 dilution in water relative to DM09. [Figure 2A] These graphs show the dose-response relationship of sweetness intensity for MNEI (Figure 2A), DM13 (Figure 2B), DM28 (Figure 2C), and DM31 (Figure 2D). [Figure 2B]These graphs show the dose-response relationship of sweetness intensity for MNEI (Figure 2A), DM13 (Figure 2B), DM28 (Figure 2C), and DM31 (Figure 2D). [Figure 2C] These graphs show the dose-response relationship of sweetness intensity for MNEI (Figure 2A), DM13 (Figure 2B), DM28 (Figure 2C), and DM31 (Figure 2D). [Figure 2D] These graphs show the dose-response relationship of sweetness intensity for MNEI (Figure 2A), DM13 (Figure 2B), DM28 (Figure 2C), and DM31 (Figure 2D). [Figure 3] This histogram shows the stability of DM13 in citrate buffer after heating at 90°C for a maximum of 10 minutes. The Y-axis represents sweetness intensity. [Figure 4] This histogram shows the stability of DM13 in citrate buffer after heating at 95°C for 30 seconds. The Y-axis represents sweetness intensity. [Figure 5A] This histogram shows the stability of DM13 after 8 weeks of storage at 21°C and 32°C. The Y-axis represents sweetness intensity. [Figure 5B] This histogram shows the stability of DM13 after 8 weeks of storage at 21°C and 32°C. The Y-axis represents sweetness intensity. [Figure 6] This spider graph shows the properties of a control ketchup prototype with 69% less added sugar and an exemplary ketchup with DM09. The results show that the control ketchup is less sweet, more acidic, more salty, and causes a stronger tingling sensation on the tongue compared to the ketchup with DM09. [Figure 7] This spider graph shows that a ketchup prototype with 69% less added sugar is less sweet, more acidic, and has a brighter color compared to full-sugar ketchup. [Figure 8] This spider graph shows that a ketchup prototype containing DM09 (with 69% less added sugar) has a sensory profile very similar to that of full-sugar ketchup. [Figure 9]This spider graph shows that ketchup containing DM28 has a similar sensory profile to ketchup containing DM09. [Figure 10] This spider graph shows that ketchup containing DM09 retains its sweetness after one month of shelf life. The changes observed in the product are typical of ketchup after one month of shelf life (darker color, more flavorful, more acidic, thicker, and less smooth texture). [Figure 11] This spider graph shows that plain yogurt with 33% less added sugar is less sweet than plain yogurt containing DM09 and with 33% less added sugar. [Figure 12] This spider graph shows that plain yogurt containing DM09 (with 33% less added sugar) has a similar sensory profile to full-sugar yogurt. [Figure 13] This spider graph shows that strawberry yogurt containing DM28 has a similar sensory profile to strawberry yogurt containing DM09. [Figure 14] This spider graph shows that plain yogurt containing DM09 has a similar sensory profile to fresh plain yogurt containing DM09 after a two-week shelf life. [Figure 15] This spider graph shows that aqueous solutions containing stevia and DM09 are sweeter than aqueous solutions containing stevia alone, at the same sweetness level equivalent. [Figure 16] This spider graph shows that aqueous solutions containing a combination of monk fruit, stevia, and DM09 are sweeter and have a shorter "delayed" release compared to aqueous solutions containing only monk fruit and stevia at the same sweetness level equivalent. [Figure 17] This spider graph shows that a lemon-flavored drink (with stevia, 50% reduced sugar content, 5°Bx equivalent) has a very similar sensory profile to stevia and DM09 (2.5°Bx equivalent each). [Figure 18]This spider graph shows that ketchup containing DM031 (with 69% less added sugar) has a very similar sensory profile to ketchup containing DM09. [Figure 19] This spider graph shows that strawberry yogurt containing DM31 has a similar sensory profile to strawberry yogurt containing DM09. [Figure 20] This spider graph shows that chewing gum containing DM09 is sweeter than chewing gum without DM09 after 30 seconds of chewing. [Figure 21] This spider graph shows that DM09 and peanut butter with 50% reduced sugar have a similar sensory profile to full-sugar peanut butter. [Figure 22] This spider graph shows that iced coffee with DM09 (70% reduced sugar) is sweeter than iced coffee without DM09 (70% reduced sugar). [Figure 23] This spider graph shows that cranberry juice (40% reduced sugar, stevia, and DM09) has a similar sensory profile to full-sugar cranberry juice. [Figure 24] This spider graph shows that cranberry juice containing DM28 is sweeter than cranberry juice containing DM09. [Figure 25] This is a spider graph showing that cranberry juice with 40% reduced sugar, stevia, and DM31 has a similar sensory profile to cranberry juice with 40% reduced sugar, stevia, and DM09. [Figure 26] This spider graph shows that dried cranberries (50% reduced sugar and DM09) are sweeter than dried cranberries without DM09 (50% reduced sugar). [Figure 27] This spider graph shows that Momo leather with DM09 is sweeter than Momo leather without DM09. [Figure 28]This spider graph shows that iced green tea with 40% reduced added sugar, plus DM09 and stevia, is sweeter than iced green tea with 40% reduced added sugar but without DM09 and stevia. [Figure 29] This spider graph shows that Maravi with 50% reduced added sugar + DM31 is sweeter than Maravi with 50% reduced added sugar but without DM31. [Figure 30A] This is a crystal structure image highlighting the changes made in DM31. Figure 30A shows the alignment of the crystal structure of DM31 (black) and the crystal structure of MNEI (PDB ID: 2o9u) (white). A smaller panel in Figure 30A shows a magnified view of the selected amino acid changes in DM31, as well as the redesigned loop. The redesigned loop resulted in increased stability, as well as new hydrogen bonds and two nearby extended beta-chains (Figure 30A, lower right panel). Figure 30B shows an overlay of the same loop region of DM31 with an additional MNEI structure available in the public database. DM31 is marked in black. [Figure 30B] This is a crystal structure image highlighting the changes made in DM31. Figure 30A shows the alignment of the crystal structure of DM31 (black) and the crystal structure of MNEI (PDB ID: 2o9u) (white). A smaller panel in Figure 30A shows a magnified view of the selected amino acid changes in DM31, as well as the redesigned loop. The redesigned loop resulted in increased stability, as well as new hydrogen bonds and two nearby extended beta-chains (Figure 30A, lower right panel). Figure 30B shows an overlay of the same loop region of DM31 with an additional MNEI structure available in the public database. DM31 is marked in black. [Figure 31A]This is a histogram showing the normalized B factor for several MNEI structures (2o9u, liv7, 5zlp), DM09, and DM31. First, the skeletal B factor was normalized separately for each structure using Z-score normalization. The B factor is shown as the mean for different secondary structure elements (Figure 31A), as well as for specific residues that are part of the redesigned loop region (E48-E54, numbered according to the sequence of the MNEI) (Figure 31B). [Figure 31B] This is a histogram showing the normalized B factor for several MNEI structures (2o9u, liv7, 5zlp), DM09, and DM31. First, the skeletal B factor was normalized separately for each structure using Z-score normalization. The B factor is shown as the mean for different secondary structure elements (Figure 31A), as well as for specific residues that are part of the redesigned loop region (E48-E54, numbered according to the sequence of the MNEI) (Figure 31B). [Figure 32] The images show the stabilizing hydrogen bonds in the crystal structures of MNEI(A), DM09(B), and DM31(C). The redesigned loop regions are highlighted with black borders. [Figure 33A] Figure 33A shows the loop region in the crystal structure of DM31 compared to the conventional definition of beta-turn (Figure 33B). The loop structure of DM31 (Figure 33A) is consistent with the schematic definition shown in Figure 33B. [Figure 33B] Figure 33A shows the loop region in the crystal structure of DM31 compared to the conventional definition of beta-turn (Figure 33B). The loop structure of DM31 (Figure 33A) is consistent with the schematic definition shown in Figure 33B. [Figure 34A] These are images of a 16% SDS-PAGE tricine protein gel, with 1 ug of in vitro digested sample stained with Coomassie blue at pre-digestion (TO), end of oral phase (3 min, M), end of gastrointestinal digestion phase (2 hours, G), and end of duodenal phase (2 hours, D). Figure 34B shows images of α-lactalbumin used as detailed positive controls M, G, and D, related to Figure 34A. [Figure 34B]These are images of a 16% SDS-PAGE tricine protein gel, with 1 ug of in vitro digested sample stained with Coomassie blue at pre-digestion (TO), end of oral phase (3 min, M), end of gastrointestinal digestion phase (2 hours, G), and end of duodenal phase (2 hours, D). Figure 34B shows images of α-lactalbumin used as detailed positive controls M, G, and D, related to Figure 34A. [Modes for carrying out the invention]

[0057] Artificial low-calorie sweeteners are readily available on the market, but many have serious side effects. For example, saccharin, widely used to sweeten foods and beverages without adding calories or carbohydrates, has been linked to cancers such as bladder cancer. Therefore, there is a significant need for alternatives to currently available artificial low-calorie sweeteners that offer an optimal sensory profile and are suitable for use in food products and beverages.

[0058] This disclosure relates to MNEI-based sweetening proteins and MNEI-flavor-modifying proteins, and is based on the identification of proteins that exhibit improved properties compared to known sweeteners. Such proteins were identified by optimization methods, e.g., various computer methods.

[0059] Surprisingly, the inventors have found that introducing various specific deletions or substitutions into the amino acid sequence of MNEI (referred to herein as the “reference protein”) results in a protein having at least one improved property compared to the reference MNEI protein. It has been suggested that at least one improved property of the protein may be important for the suitability and use of the modified MNEI protein in food and beverage applications.

[0060] Specifically, as shown in the following examples, proteins (referred to herein as “modified proteins” or “designer proteins”) exhibited improved sensory profiles and / or stability compared to their reference proteins. Sensory profiles relate to taste profiles (e.g., sweetness, aftertaste, and lingering flavor), as described herein.

[0061] Accordingly, in its broadest aspect, this disclosure relates to a modified MNEI protein comprising an amino acid sequence having at least two amino acid deletions, substitutions, and / or insertions compared to the sequence of a reference MNEI protein, wherein the modified protein has at least one improved food-related property compared to the reference MNEI protein.

[0062] At least one improved food-related property is a property that increases the suitability of the modified protein in food and beverage applications, such as flavor, texture, taste, sweetness threshold, sweetness level, sweetness profile, sensory profile, sweetness dynamics, stability (structural and functional), heat resistance, suitability to food matrices, shelf life, masking and / or enhancement of other flavors, off-flavor, taste onset, aftertaste, taste smoothness, or sugar-like taste.

[0063] In some embodiments, at least one food-related property is a sensory property. As used herein, the term “sensory property” refers to a change in sensory impression, for example, determined by taste. Examples of sensory properties include sweetness (sugar-like flavor), sweetness dynamics (onset time, lingering time, taste duration), absence of off-flavors (e.g., metallic taste), and sweetness profiles such as masking or enhancement of other tastes. For example, improved properties relate to increased sweetness, reduced onset time, or reduced aftertaste.

[0064] According to some embodiments, the modified protein can be considered a sugar substitute if at least one of its properties is a sensory property. In some embodiments, the at least one food-related property is at least one of sweetness, reduced onset time, or reduced aftertaste.

[0065] In some embodiments, at least one food-related property is stability. In some embodiments, stability is at least one of the following: thermal stability, longer shelf life, stability to low pH, salt concentration stability, ionic strength stability, or stability in fat-containing or protein-containing matrices. In some embodiments, at least one food-related property is thermal stability.

[0066] In some embodiments, at least one food-related property is increased shelf-life stability. For example, the modified protein may be stable for at least one week, two weeks, one month, or even one year.

[0067] Storage life stability is assessed by tasting using differential scanning calorimetry, differential scanning fluorescence quantification, circular dichroism, and sensory analysis. In some embodiments, the taste of the food is maintained and the proteins remain intact.

[0068] As detailed above, the modified MNEI protein may be used in combination with at least one additional food component. In some embodiments, the at least one food-related property may refer to a synergistic effect between the modified MNEI protein and at least one food component. According to some embodiments, this synergistic effect may affect taste enhancement, taste blocking, or taste modification. Non-limiting examples of food components include artificial or natural flavorings, food additives, food dyes, preservatives, fillers, or additional sugar additives. Food components may have taste masking or enhancing effects.

[0069] As described herein, the reference protein is a taste-modifying protein and / or taste-enhancing protein and / or taste protein, specifically a sweet taste protein. Taste-modifying proteins can improve the sensory profile and, for example, add sweetness to non-sweet substances, such as water and acidic substances. As used herein, taste proteins are known to bind to taste receptors and induce taste. As used herein, sweet taste proteins are known to bind to sweet taste receptors and induce the sensation of sweetness. Non-exclusive examples of sweet taste receptors include taste receptor heterodimers consisting of two subunits, such as type 1 member 1 (TAS1R1, Uniprot ID: TS1R1 HUMAN), taste receptor type 1 member 2 (TAS1R2, T1R2, TR2, UniProt-Q8TE23), and taste receptor type 1 member 3 (TAS1R3, T1R3, UniProt-Q7RTX0).

[0070] In some embodiments, the reference protein is a naturally occurring protein. In some other embodiments, the reference protein is found in plants, such as tropical plants. Non-limiting examples of plants include at least one of mavinlaw, oubli, serendipity berry, katemfe, miracle fruit berry, or lemba.

[0071] In some embodiments, the reference protein is monellin.

[0072] In some embodiments, the reference protein is monellin, which consists of an A chain (GenBank registry number P02881) and a B chain (GenBank registry number P02882).

[0073] In some embodiments, the reference protein is MNEI.

[0074] The main difference between wild-type monellin and MNEI is the region where two subunits are linked together using a glycy-Phe dipeptide, forming a single-chain monellin called MNEI.

[0075] In some embodiments, the reference protein is a sequence not found in nature and is therefore called a synthetic protein, or engineered protein, or designer protein. A synthetic protein may include all or part of the amino acid sequence of a naturally occurring protein (all or part of the polypeptide chain of the protein), or part thereof. For example, the reference protein may include a binding modification of a naturally occurring protein that results in a single polypeptide chain corresponding to a naturally occurring protein, such that at least two polypeptide chains of the wild-type protein are covalently linked by other amino acids.

[0076] In some embodiments, the reference protein is a modified monellin protein known as MNEI.

[0077] In some embodiments, the reference protein is single-chain monellin (MNEI) protein (SEQ ID NO: 45). The MNEI amino acid numbers referred to herein follow Protein Databank (PDB) ID 209u.

[0078] The modified proteins described herein can be designed by a variety of methods.

[0079] In some embodiments, protein design is performed using computer tools or by professional protein design and structural biology methods, such as site-directed mutagenesis, protein manipulation, or directed evolution, as further described below. The inventors have developed computer methodologies based on sequence data, structural data, and / or evolutionary data of a reference flavor protein, as well as other proteins that have local or global similarities to the reference flavor protein in sequence and / or structural features. The computer methods developed and applied herein have enabled the inventors to design proteins having specific amino acid substitutions that are energetically advantageous and therefore predicted to have improved traits such as thermal stability, halostability, pH stability, shelf life, folding, and solubility. Specifically, Computational Protein Design (CPD) was applied to specific sites or regions within the reference protein structure and / or sequence that are not necessary for functional binding to the receptor. Furthermore, CPD enabled the inventors to limit the substitutions to a predetermined set of amino acids that conform to the desired improved features. A predetermined set of amino acids exists in both the input data, i.e., the region of the protein subjected to CPD, and the output data, i.e., the positions and types of amino acids present in the resulting modified protein.

[0080] For example, by using CPD, it is possible to replace "non-ideal" amino acids (e.g., hydrophilic amino acids in the hydrophobic core or hydrophobic amino acids on the outer surface region) with "ideal" amino acids (e.g., hydrophilic amino acids in the outer surface region and hydrophobic amino acids in the hydrophobic core).

[0081] While not bound by theory, the inventors suggest that substituting hydrophobic amino acids with hydrophilic amino acids on the external surface region reduces nonspecific binding to the oral cavity and thus reduces lingering aftertaste.

[0082] The methodologies developed herein involve searching for “stabilizing substitutions,” such as amino acid substitutions that reduce the overall energy of a protein structure. The overall energy can be calculated by applying algorithms known in the art. Non-limiting examples of such algorithms include Rosetta, OSPREY (M. Hallen, J. Martin, et al., Journal of Computational Chemistry 2018;39(30):2494-2507), or EnCoM (Frappier V, Chartier M, Najmanovich RJ. Nucleic Acids Res. 2O15;43(W1):W395-400). These CPD methods are then focused and filtered by a series of orthogonal methods, including evolutionary sequence and structural consensus, regular and high-temperature molecular dynamics (MD), as well as other dynamic simulations, correlated mutational analysis (CMA), surface electrostatic analysis, visual inspection, and analysis of cavities, hydrophobic patches, unfilled hydrogen bonds, etc.

[0083] Amino acid substitutions are based on the following considerations: (a) surface electrostatic potential and (absence of) hydrophobic patches on the surface; (b) retention of the protein's isoelectric point (pI) within a specific range; (c) analysis of intraprotein cavities; (d) dynamic stability including correlated mutation analysis, normal mode analysis, and root mean square fluctuation (RMSF) in high-temperature or room-temperature kinetics; (e) entropy and / or enthalpy components of substitutional energy; (f) visualization of specific substitutions; (g) acceptable amino acid types in the family of related proteins as reflected by evolutionary conservation analysis of selected multiple sequence alignments (MSAs); and (h) frequency of substitutions as reflected in low pseudo-energy CPD calculations.

[0084] The computer method includes one or more of the following steps: (1) Multiple Sequence Alignment (MSA) or Multiple Structure Alignment. In this step, DNA sequences and / or protein sequences having similarity to the target reference protein or its fragments are queried in public databases. Based on the results obtained, a Multiple Sequence Alignment (MSA) or Multiple Structure Alignment is constructed and the conservation rate is calculated. A decision is made regarding the level of CPD to be performed according to the MSA results. In non-conserved positions, all amino acids (with or without cysteine) are acceptable in the CPD, but in more conserved positions, the CPD is limited to residues with similar properties (charge, size, internal dynamics, etc.). This step involves limiting substitutions at each position based on biophysical knowledge and conservation data. The MSA may produce a Position Specific Substitution Matrix (PSSM) in which each position along the sequence is described in a manner correlated with the relative abundance of each amino acid, possibly taking into account the potential probability of amino acid substitution, deletion, or insertion. (2) Analysis of protein function and structure-function-kinetic relationships. In this step, a database of substitutions with known effects (on activity, structure, binding, etc.) is constructed using prior knowledge. Based on prior knowledge, substitutions and adjacent positions (e.g., distance of 0.5-1 nm) known to interfere with protein stability and / or function are limited to and not substituted during CPD. (3) CPD. This step is partially performed using designated software such as Rosetta, Osprey, SCWRL, PyMol, and AlphaFold. The energy of the reference protein 3D structure / model is minimized before performing deterministic CPD. CPD may include site-directed amino acid substitution, where one amino acid is replaced by another, or substitution of protein regions with other amino acid sequences that result in proteins of different lengths. The latter can be done by reconstructing regions such as loops using the abu initio method, or by extracting regions from other proteins, a method that may be called "grafting". For each reference protein, multiple models are considered. (4) Selection: Models of proteins with the lowest energy are collected. MSAs are assembled on these models and conserved sequences are determined. Based on biochemical and biophysical prior knowledge, a subset of substitutions is selected. These subsets represent substitutions at one or more positions that occur frequently during CPD. Each subset is then modeled on the 3D structure of the protein to minimize its energy. The lowest energy subset is then selected for further computational and experimental validation.

[0085] One of the considerations used in CPD is whether to substitute amino acids in and around the receptor binding site. The determination of amino acid residues important for taste receptor binding can generally be done by single-point substitutions of various amino acids. As detailed in the examples herein, the inventors used computer analysis to characterize putative binding sites to taste receptors. The inventors identified several novel binding sites in taste receptors that bind to reference and modified proteins.

[0086] Another consideration in CPD is increasing thermal stability while retaining the functional plasticity required for receptor binding, which is often inherently related to protein rigidification. Proteins must undergo several conformational changes (also known as "functional plasticity") to activate their receptors. Therefore, we focused on regions that can be rigidified while preserving regions where functional plasticity must be maintained.

[0087] It should be noted that the modified MNEI protein is based on the reference MNEI protein (amino acid sequence), and therefore any features / characterizations described herein with respect to the modified MNEI protein are provided in relation to the reference corresponding MNEI protein.

[0088] As described herein, a modified MNEI protein comprises an amino acid sequence having at least two, at least three, at least four, at least five, at least six, at least ten, at least fifteen, or at least eighteen amino acid substitutions, deletions, or insertions relative to a reference MNEI protein (reference amino acid sequence).

[0089] In some embodiments, the modified MNEI protein contains 2 to 20 amino acid substitutions, deletions, or insertions, 2 to 10 amino acid substitutions, 3 to 10 amino acid substitutions, or 3 to 6 amino acid substitutions relative to the reference MNEI protein (reference amino acid sequence). The range as used herein includes, for example, a range limit such that 3 to 6 includes 3, 4, 5, and 6.

[0090] In some embodiments, the modified MNEI protein comprises at least two, at least three, at least four, at least five, at least six, at least ten, at least fifteen, or at least eighteen amino acid substitutions, deletions, or insertions relative to the reference MNEI protein having the sequence described in SEQ ID NO: 45.

[0091] In some embodiments, the modified MNEI protein contains an amino acid sequence that is 40% to 98% identical to that of the reference MNEI protein. In some embodiments, the modified MNEI protein contains an amino acid sequence that is 90% to 98% identical to that of the reference amino acid sequence.

[0092] In some embodiments, the modified MNEI protein contains an amino acid sequence that is 60% to 90% identical to the reference amino acid sequence. In some embodiments, the modified MNEI protein contains an amino acid sequence that is 70% to 90% identical to the reference amino acid sequence.

[0093] In some embodiments, the modified MNEI protein contains an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity with the amino acid sequence described in Sequence ID No. 45.

[0094] In some embodiments, the modified MNEI protein contains an amino acid sequence that has 90% to 98% identity with the amino acid sequence described in SEQ ID NO: 45.

[0095] The percentage of identity between two or more amino acid sequences is determined by comparing the two or more sequences and aligning them for maximum similarity. In the context of this disclosure, sequences (amino acids) described herein that have a percentage of identity are considered to have the same function / activity as the reference sequence from which the identity is calculated.

[0096] In some embodiments, the modified MNEI protein contains an amino acid sequence that is 40% to 98% similar to the amino acid sequence of the reference MNEI protein. In some embodiments, the modified MNEI protein contains an amino acid sequence that is 90% to 98% similar to the reference amino acid sequence.

[0097] In some embodiments, the modified MNEI protein contains an amino acid sequence that is 60% to 90% similar to the reference amino acid sequence. In some embodiments, the modified MNEI protein contains an amino acid sequence that is 70% to 90% similar to the reference amino acid sequence.

[0098] In some embodiments, the modified MNEI protein contains an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% similarity to the amino acid sequence described in Sequence ID No. 45.

[0099] In some embodiments, the modified MNEI protein contains an amino acid sequence having 90% to 98% similarity to the amino acid sequence described in SEQ ID NO: 45.

[0100] In some embodiments, the modified MNEI protein comprises the amino acid sequence described in one of SEQ ID NOs: 1 to 21, a variant thereof, or the aforementioned fragment. In particular, the modified MNEI protein may comprise the amino acid sequence described in one of SEQ ID NOs: 1, 4, 16, 19, or 24, a variant thereof, or the aforementioned fragment. The modified MNEI protein may also comprise a sequence that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to one of SEQ ID NOs: 1 to 21, particularly one of SEQ ID NOs: 1, 4, 16, 19, or 24.

[0101] As used herein, sequence similarity or sequence homology refers to the amount (%) of conserved amino acids, such as leucine and isoleucine, that have similar physicochemical properties.

[0102] In determining sequence identity, gaps are not counted, and sequence identity is determined for the shorter of the two sequences. In this context, it should be noted that the length of the reference MNEI protein (amino acid sequence) may be the same as or different from that of the modified MNEI protein (amino acid sequence).

[0103] The terms "amino acid sequence" and / or "polypeptide chain" are used to describe proteins that have an amino acid sequence or polypeptide chain. Therefore, the term "reference protein" corresponds to the term "reference amino acid sequence," and the term "modified protein" corresponds to the term "modified amino acid sequence." It should be noted that the terms "amino acid sequence" and / or "polypeptide chain" include sequences with a 3D structure as well as sequences without a 3D structure.

[0104] As used herein in connection with this disclosure, the term “fragment” is a shortened term, i.e., a protein or peptide derived from a full-length protein lacking at least one amino acid. Such a fragment may contain at least 10 or more consecutive amino acids of the primary sequence of the protein, e.g., 20 or 30 or more.

[0105] As used in this disclosure, the term “variant” refers to derivatives of proteins or peptides, including, for example, alterations of the amino acid sequence by substitution, deletion, insertion, or chemical modification. Such alterations do not reduce the functionality of the protein or peptide in some embodiments. Such variants include proteins in which one or more amino acids are replaced by their respective D-stereoisomers or by amino acids other than the 20 naturally occurring amino acids, such as ornithine, hydroxyproline, citrulline, homoserine, hydroxylysine, and norvaline. However, such substitutions may be conservative, i.e., amino acid residues are replaced by chemically similar amino acid residues.

[0106] As part of the computer optimization process, modified proteins may be selected from a large output population of amino acid sequences after computer analysis, bioinformatics analysis, or structural-biological analysis, based on energetic considerations, i.e., sequences with low energy.

[0107] Energy calculations can be applied to the entire amino acid sequence, or alternatively, limited to specific regions or selected amino acids within a protein. In the latter case (different regions or selected amino acids), the information can be integrated to measure the energy of the entire protein.

[0108] Each calculation of an amino acid sequence (e.g., a modified protein) can be performed by combining a physical-based approach (also known as a biophysical method) and a statistical-based approach (also known as a knowledge-based approach or an informatic method), such as by using Rosetta energy units (REUs). Rosetta energy units (REUs) are an algorithm in Rosetta software, a package of algorithms for computer modeling and protein structure analysis. Rosetta software enables remarkable scientific advances in computational biology, including de novo protein design, enzyme design, ligand docking, and structural prediction of biological macromolecules and macromolecular complexes. The Rosetta energy function is a combination of a physical-based approach and a statistical-based approach that does not correspond to any actual physical energy unit. Rosetta energy is an arbitrary measure and is sometimes referred to as REU ("Rosetta energy unit").

[0109] In some embodiments, REU may be calculated for an entire protein sequence containing at least one amino acid substitution. In some other embodiments, REU may be calculated for at least one region of the entire protein sequence containing at least one amino acid substitution. In some other embodiments, REU may be calculated for at least one amino acid substitution in the entire protein sequence.

[0110] In some embodiments, the modified protein has an energy of less than -182 REU. In some embodiments, the modified protein has an energy of about -190 REU. In some embodiments, the modified protein has an energy of about -195 REU. In some embodiments, the modified protein has an energy of less than -195 REU. In some embodiments, the modified protein has an energy of less than -196 REU. In some embodiments, the modified protein has an energy of less than -197 REU. In some embodiments, the modified protein has an energy of less than -198 REU. In some embodiments, the modified protein has an energy of about -198 REU. In some embodiments, the modified protein has an energy of less than -198.4 REU. In some embodiments, the modified protein has an energy of less than -200 REU. In some embodiments, the modified protein has an energy of less than -203 REU. In some embodiments, the modified protein has an energy of less than -206.4 REU. In some embodiments, the modified protein has an energy of less than -210 REU. In some embodiments, the modified protein has an energy of less than -214.6, expressed in REU.

[0111] In some embodiments, the modified protein has an energy of less than -270.11 REU. In some embodiments, the modified protein has an energy of less than -300 REU. In some embodiments, the modified protein has an energy of less than -350 REU. In some embodiments, the modified protein has an energy of less than -400 REU. In some embodiments, the modified protein has an energy of less than -410 REU. In some embodiments, the modified protein has an energy of less than -418 REU. In some embodiments, the modified protein has an energy of less than -420 REU. In some embodiments, the modified protein has an energy of less than -430 REU. In some embodiments, the modified protein has an energy of less than -433 REU.

[0112] In some embodiments, the modified protein has an energy range of -182 to approximately -214.6 REU. In some other embodiments, the modified protein has an energy range of -195 to approximately -214.6 REU. In some other embodiments, the modified protein has an energy range of -197 to approximately -214.6 REU.

[0113] As described herein, modified proteins may result from amino acid substitutions or deletions in various regions of a protein. As used herein, “region of protein” refers to an amino acid sequence or structural motif that is part of a protein sequence (amino acid sequence) or structure. Non-limiting examples of protein regions include protein surfaces, protein cores, protein loops, secondary structure elements, secondary structure cappings, disulfides, binding sites, linkers, hydrophobic patches, or hydrophobic regions of a protein.

[0114] Amino acid substitutions in a reference protein are not limited to specific protein regions or sequences. Regions of a reference protein that may contain amino acid substitutions include the reference protein surface, hydrophobic core, or loop regions (also referred to as regions lacking secondary structure), secondary structure edges (also referred to as secondary structure capping regions), disulfide regions, binding site regions, linker regions, and hydrophobic patch regions.

[0115] As used herein, “reference surface region,” “reference core region,” or “reference disulfide bond or loop region” may refer to the corresponding region of a reference protein, which may be a reference MNEI protein.

[0116] In some embodiments, the reference protein may be substituted within a limited region of the reference protein structure and / or sequence. In some embodiments, the reference protein may be substituted in the surface region. In some embodiments, the reference protein may be substituted in the core region. In some embodiments, the reference protein may be substituted by disulfide bonds. In some embodiments, the reference protein may be substituted in the loop region. In some embodiments, the substitution of two or more amino acids is located on the surface of the reference protein.

[0117] In some embodiments, the reference protein may be replaced with a limited region that is not in the area adjacent to the predicted or known binding site of the reference protein to the receptor. In this context, “adjacent” may mean 4–7 Å from the binding interface.

[0118] In some embodiments, the reference protein may be substituted in different regions within the reference protein structure and / or sequence. In some embodiments, the reference protein may be substituted in at least the surface region, core region, disulfide bond or loop region, or any combination thereof.

[0119] As used herein, the protein surface region is an area that has partial or complete solvent contactability (SASA - solvent-contactable surface area). As used herein, the protein core region is an area that is not solvent-contactable, having less than 50% amino acid relative SASA (solvent-contactable surface area) for the inner core.

[0120] In some embodiments, the modified protein contains an amino acid sequence that has 10% to 98%, 20% to 98%, 30% to 98%, 40% to 98%, 50% to 90%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 98% identity with respect to the reference surface region in the surface region.

[0121] In some embodiments, the modified protein contains an amino acid sequence that has 10% to 98%, 20% to 98%, 30% to 98%, 40% to 98%, 50% to 90%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 98% identity with respect to the reference hydrophobic core (hydrophobic patch) region.

[0122] In some embodiments, the modified protein contains an amino acid sequence that has 10% to 98%, 20% to 98%, 30% to 98%, 40% to 98%, 50% to 90%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 98% similarity to the reference hydrophobic core (hydrophobic patch) region.

[0123] In some embodiments, the modified protein contains an amino acid sequence having 3(3) to 40(40) amino acid substitutions, 4 to 30 amino acid substitutions, and 5 to 30 amino acid substitutions in the surface region relative to the reference surface region.

[0124] In some embodiments, the modified protein contains an amino acid sequence having at least 1(1), 2(2), 3(3), at least 4, at least 5, at least 6, at least 10, at least 15, at least 18, at least 20, at least 25, or at least 30 amino acid substitutions in the surface region relative to the reference surface region.

[0125] In some embodiments, the modified protein contains an amino acid sequence that has 20%, 30%, 50%, 80%, 90%, 95%, or 98% identity with respect to the reference core region in the core region.

[0126] In some embodiments, the modified protein contains an amino acid sequence that is 20%, 30%, 50%, 80%, 90%, 95%, or 98% similar in the core region to the reference amino acid sequence core region.

[0127] In some embodiments, the modified protein includes an amino acid sequence having 1 to 5 amino acid substitutions in the core region relative to the reference core region.

[0128] In some embodiments, the modified protein contains an amino acid sequence that has 90%, 95%, or 98% identity with respect to the reference region that binds to the receptor in question, in the receptor-binding region (receptor-binding site).

[0129] In some embodiments, the modified protein contains an amino acid sequence that has 90%, 95%, or 98% similarity to the reference receptor binding site at the receptor binding site.

[0130] In some embodiments, the receptor binding site of the reference protein is not substituted in the modified protein.

[0131] In some embodiments, at least one of the disulfide bonds is removed, and the region around them is redesigned with 8 to 20 substitutions around each of the removed disulfide bonds.

[0132] Amino acids may be referred herein by either their commonly known three-letter or one-letter symbols as recommended by the IUPAC-IUB Biochemical Nomenclature Commission. As used herein, amino acid substitution refers to a change from one amino acid to another. This typically results from a point mutation in the DNA sequence caused by a non-synonymous missense mutation, which alters the codon sequence to encode a different amino acid than the reference. Amino acid substitutions can generally affect the function or structure of a protein, depending on how similar or dissimilar the substituted amino acids are and their positions in the sequence or structure. For example, amino acid substitutions may be based on similarity in size, polarity, charge, solubility, hydrophobicity, hydrophilicity, bulk (or flexibility), beta-branching, tendency to be present in a particular secondary structure or a particular solvent-contactable region, aromaticity, ability to confer specific binding interactions (hydrogen bonds, salt bridges, polar and nonpolar interactions), pK, ability to bind to sugars and other post-translational modifiers, and / or amphiphilicity of the residues involved.

[0133] In some embodiments, amino acid substitutions can be conservative substitutions. Such substitutions involve changing one amino acid to another amino acid that exhibits similar properties. A conservative amino acid substitution (also referred to as a conservative amino acid "substitution" or conservative amino acid mutation) is an amino acid substitution in a protein that changes a given amino acid to a different amino acid that has similar biochemical, structural, and / or chemical properties.

[0134] For example, amino acids can be classified into six main classes based on their structure and the general chemical characteristics of their side chains (R groups). Aliphatic compounds: Isoleucine (I), Leucine (L), Glycine (G), Alanine (A), Valine (V) Hydroxyl or sulfur / selenium-containing: serine (S), cysteine ​​(C), threonine (T), methionine (M), Circular: Proline (P) Aromatic compounds: Phenylalanine (F), tyrosine (Y), tryptophan (W) Basic: Histidine (H), Lysine (K), Arginine (R) Acids and their amides: aspartate (D), glutamate (E), asparagine (N), glutamine (Q).

[0135] Furthermore, each of the following groups contains other exemplary amino acids that are conserved substitutions with each other. 1) Very small: Alanine (A), Glycine (G), 2) Negative charge: Aspartic acid (D), Glutamic acid (E), 3) Polarity (amidated carboxyl side chain): asparagine (N), glutamine (Q), 4) Positive charge: Arginine (R), Lysine (K), 6) Aromatics: Phenylalanine (F), tyrosine (Y), tryptophan (W), and possibly histidine (H), 7) Low polarity: serine (S), threonine (T), 8) Sulfur content: Cysteine ​​(C), Methionine (M) 9) Small: Ala (A), Glycine (G), Serine (S).

[0136] 10) Beta-branched: valine (V), isoleucine (I), and possibly threonine (T), 11) Polarity: Asparagine (N), Glutamine (Q), Serine (S), Threonine (T),

[0137] Nevertheless, there are numerous clusters of amino acids that result in multiple amino acid indices, each highlighting a different aspect of amino acid characteristics; see, for example, the hundreds of such indices in the AA index database at https: / / www.genome.jp / AAindex / . As a result, some of the conserved substitutions may represent other important features for protein compatibility for industrial use in the food and beverage industry, such as nonspecific binding to the tongue or other aspects of the sensory profile.

[0138] The additional preservation analysis is based on the following: -Nonpolar "hydrophobic" amino acids are selected from the group consisting of valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tryptophan (W), cysteine ​​(C), alanine (A), tyrosine (Y), histidine (H), threonine (T), serine (S), proline (P), glycine (G), arginine (R), and lysine (K). - "Polar" amino acids are selected from the group consisting of arginine (R), lysine (K), aspartic acid (D), glutamic acid (E), asparagine (N), and glutamine (Q). - The "positively charged" amino acids are selected from the group consisting of arginine (R), lysine (K), and histidine (H), and - "Acid" amino acids are selected from the group consisting of aspartic acid (D), asparagine (N), glutamic acid (E), and glutamine (Q).

[0139] In some embodiments, the substitution is a radical substitution. A radical substitution is the exchange of one amino acid for another amino acid having different properties.

[0140] The degree of sequence similarity and / or sequence identity between a reference protein and a modified protein can generally affect the properties of the modified protein. For example, numerous substitutions can affect binding kinetics, folding kinetics, solubility, thermal stability, halo stability, pH stability, shelf life, binding to non-aqueous particles (e.g., proteins or fats in food matrices, or hydrophobic regions in the oral cavity), 3D structure, and its activity and related properties. The computer methods developed and applied herein provide a complete understanding of putative amino acid residues for substitutions that result in improved modified proteins.

[0141] According to some embodiments, the reference protein is MNEI having the amino acid sequence described in SEQ ID NO: 45. As shown in Example 1 below, CPD analysis revealed several amino acids as targets for substitution or deletion.

[0142] In some embodiments, at least one amino acid substitution is a conservative substitution. In some embodiments, at least one amino acid substitution is a radical substitution. In some embodiments, two or more amino acids are substituted.

[0143] Amino acid substitutions in MNEI, including multiple mutations, have been previously reported. For example, Zheng et al. reported a novel dual-mutant MNEI-based protein with improved sweetness and stability. Specifically, Zheng et al. demonstrated that a single substitution of E2N in MNEI resulted in a 3-fold improvement in sweetness and a slight decrease in stability. Zheng et al. further showed that introducing additional substitutions, E23A or Y65R, in addition to the E2N substitution (e.g., E2N / E23A, E2N / Y65R), did not affect sweetness.

[0144] In some embodiments, at least two or at least three of the at least three amino acid substitutions in the reference protein, which is MNEI, are conservative substitutions.

[0145] As described herein, the modified MNEI proteins described herein have improved food-related properties. The sweetness profile of the modified proteins, including sweetness (sugar-like flavor), lack of off-flavor, reduced onset time, and reduced aftertaste, can be determined by any known taste test known in the art. For example, comparison with the sweetness of sucrose or other sweeteners can be performed by a taste panel, and the sweetness can be graded as detailed in the following examples.

[0146] Comparisons can be made, for example, by determining the threshold of the modified protein compared to known sweeteners such as sucrose, by determining the minimum concentration required to induce a sweet taste sensation, or by determining a sweetness profile evaluation that includes features such as sweetness profile, sweetness onset time, aftertaste, mouthfeel, aftertaste, off-flavor, and masking of undesirable tastes.

[0147] As used herein, the term "characteristics affecting sweetness" encompasses the sensation of sweetness determined by at least one of the following: a sweetness threshold of about 0.28 mg / L, a sweetness threshold of about 0.5 mg / L or greater, and a sweetness duration of about 1 to 20 seconds, sometimes 2 to 18 seconds, and sometimes 2 to 4 seconds.

[0148] The modified MNEI protein binds to sweet taste receptors, just like the reference MNEI protein.

[0149] In some embodiments, the modified MNEI protein has a perceived sweetness threshold that is 300 to 16,000 higher by weight than sugar.

[0150] The sensory profile includes taste dynamics, which show the intensity of taste over time, namely the onset duration (time until taste is perceived), taste duration, and aftertaste duration (corresponding to the Gauss tail). Additional features include off-flavors (e.g., due to binding to other receptors), mildness of taste, metallic and other off-flavors, synergistic effects with other components (e.g., masking and enhancement of other flavors or undesirable tastes such as stevia), mouthfeel, and astringency.

[0151] In some embodiments, the modified protein is characterized by being equal to or improved upon with respect to the reference protein in at least one of the following: (1) structural thermal stability, (2) functional thermal stability, (3) pH stability, (4) solubility in water or a partially aqueous environment (e.g., a food containing fat), or (5) shelf life stability.

[0152] The modified proteins described herein are characterized by sweetness and other taste effects that can be used as sweeteners in the preparation of orally delivered products (masking of undesirable tastes, less aftertaste, less lingering taste, less off-flavor, umami, and a better mouthfeel).

[0153] Modified proteins can be used as flavor modifiers or flavor enhancers.

[0154] The modified proteins described herein are intended for use as oral products. In some embodiments, the products are food or beverage products, dietary supplements, or pharmaceuticals. For the preparation of products, the proteins described herein may be combined with any food-grade additives. Food or beverage products may be provided and used in any solid-dry form, including but not limited to fine powders, freeze-dried products, granules, tablets, etc. In some embodiments, the composition is provided in liquid form, for example, as a solute in water (aqueous solution).

[0155] Products containing modified proteins may have a variety of applications. These include, but are not limited to, use as sweeteners, flavorings, enhancers, masking agents, and flavor-characterizing proteins in the food and beverage industry (such as fruit and vegetable juices and nectars, soft drinks, ready-to-drink beverages, syrups, functional drinks, and sports drinks), the dairy industry (i.e., dairy products, yogurt, and puddings), the pharmaceutical industry, the naturopathic industry, the functional food industry (e.g., functional food bars), and other healthcare products (e.g., toothpaste and mouthwash), the confectionery, candy, and gum industry, vegetables (e.g., ketchup or sauces), or any other applications requiring the use of flavor-modifying compositions as excipients or additives.

[0156] According to some embodiments, additional food ingredients are selected from the group consisting of sucrose, fructose, glucose, agave nectar, brown rice syrup, date sugar, honey, maple syrup, molasses, monk fruit, sugar alcohols, rare sugars, steviol glycosides, aspartame, sucralose, acesulfame potassium, and dietary fiber.

[0157] In some embodiments, the modified protein has equal or improved structural thermal stability compared to the reference protein.

[0158] The terms “structural thermal stability” or “thermal stability,” as used herein, refer to the ability of a modified protein to maintain its 3D structure at temperatures higher than the temperature of the reference protein. The 3D structural stability of a protein can be measured by any method known in the art, such as circular dichroism (CD), thermal shift assays like differential scanning fluorescence (DSF) or differential scanning calorimetry (DSC), or titration using a protein denaturant such as guanidinium chloride. 3D protein structure can affect protein function. Notably, the shelf life and thermal stability required for food and beverage products may relate to structural thermal stability, which can be measured in different ways. For example, pasteurization (or heat treatment during the preparation of a good, consumer-packaged final product) can be applied by different protocols and relates to the heat resistance that maintains the protein structure for very short periods of time.

[0159] In some embodiments, the modified protein has equal or higher functional thermal stability than the reference protein. The term "functional thermal stability," as used herein, refers to the ability of the modified protein to retain its function after exposure to high temperatures compared to the reference protein.

[0160] In some embodiments, the modified proteins described herein can maintain their sweetness effect after exposure to higher temperatures or for a limited time. In other words, there is no apparent change in sweetness or sensory profile after exposure of the product to temperatures above room temperature, sometimes up to 50°C, sometimes up to 100°C, or even up to 150°C. The function of the protein, for example, sweetness, can be measured by sensory testing after the protein has been cooled to a temperature at which it can perceive its taste.

[0161] In some embodiments, the modified protein has equal or higher pH stability than the reference protein. pH stability refers to the long-term stability of the modified protein over a wider pH range than the reference protein; that is, the modified protein maintains its 3D structure and / or function after the product is exposed to any pH between 3 and 8, sometimes between 4 and 8. For example, sodas like cola have a pH of 2.3 to 2.5, at which point some of the sweetening proteins are unstable and lose their functionality quickly or after a shorter time than the normal shelf life of the beverage.

[0162] In some embodiments, the modified MNEI protein has higher solubility than the reference MNEI protein. Solubility can be in aqueous, partially aqueous, or non-aqueous environments, such as foods containing fat.

[0163] In some embodiments, the modified MNEI protein has an improved shelf life compared to the reference MNEI protein. Improved shelf life means that no change in sweetness (function) or physical degradation (e.g., change in color, phase separation, etc.) is detected in the product containing the composition after exposure to any temperature up to 150°C, sometimes any temperature between 4°C and 150°C, or 100°C.

[0164] In some other embodiments, the modified MNEI protein is characterized by at least one of the following, which is equal to or improved upon the reference MNEI protein: (1) folding dynamics, (2) post-translational modification (e.g., glycosylation or acetylation) pattern of the protein differs from the reference protein, and (3) the number of disulfide bonds is greater than that of the reference MNEI protein which has no disulfide bonds.

[0165] In some embodiments, the modified MNEI protein has folding kinetics equal to or higher than those of the reference MNEI protein. That is, the rate of protein folding from an unfolded or partially folded structure is faster (as assessed, for example, by molecular dynamics or in silico by experimental in vitro or in vivo methods). Alternatively, faster folding kinetics refer to slower, unfolded kinetics in denaturation experiments, for example, by denaturing titration (e.g., guanidinium chloride and / or high-concentration urea) or other methods.

[0166] In some embodiments, the modified MNEI protein is characterized by an expression yield equal to or higher than that of the reference MNEI protein in the host organism being evaluated.

[0167] In some embodiments, the modified MNEI protein has a pI value of 8.6–9.5.

[0168] The modified MNEI proteins described herein are characterized by sweetness and other taste effects that can be used as sweeteners in the preparation of orally delivered products (masking of undesirable tastes, less aftertaste, less lingering flavor, less off-flavor, less onset of lingering flavor, and umami).

[0169] Modified MNEI proteins can be used as flavor modifiers or flavor enhancers.

[0170] The modified MNEI proteins described herein are intended for use as oral products. In some embodiments, the products are food products, dietary supplements, or pharmaceuticals. For the preparation of products, the proteins described herein may be combined with any food-grade additives. Food products may be provided and used in any solid-dry form, including but not limited to fine powders, freeze-dried products, granules, tablets, etc. In some embodiments, the composition is provided in liquid form, for example, as a solute in water (aqueous solution).

[0171] Products containing the modified MNEI protein may have a variety of applications. These include, but are not limited to, use as a sweetener, flavoring, enhancer, or masking agent in the food and beverage industry (such as fruit and vegetable juices and nectars, soft drinks, ready-to-drink beverages, syrups, functional drinks, and sports drinks), the dairy industry (i.e., dairy products, yogurt, and puddings), the pharmaceutical industry, the naturopathic industry, the functional food industry, and other healthcare products (e.g., toothpaste and mouthwash), confectionery, candy, and gum industries, vegetables (e.g., ketchup or sauces), or any other applications requiring the use of the flavor-modifying composition as an excipient or additive (each of which constitutes a separate embodiment of the present disclosure).

[0172] The product may contain additional food ingredients. In some embodiments, the food ingredient is a sweetener, such as a steviol glycoside. The combination of the modified proteins described herein with steviol glycosides produces a synergistic effect. Therefore, in some embodiments, the product contains at least one modified protein represented by SEQ ID NOs: 1-21 and a steviol glycoside.

[0173] When stevia (indicated herein as steviol glycoside or a mixture thereof) and / or a variant thereof is combined with the modified protein of the present invention in the range of 0.5°Bx to 8°Bx sucrose equivalents, the modified protein represents a substitution of 30% to 70% of the sucrose sweetness. The perceived sweetness intensity is at least 100% of the stevia solution at 0.5°Bx to 8°Bx sucrose equivalents. The perceived residual sensory profile is superior to 100% of the stevia solution at 0.5°Bx to 8°Bx sucrose equivalents.

[0174] The perceived acidity profile is superior to that of 100% stevia solution at sucrose equivalents of 0.5°Bx to 8°Bx.

[0175] According to some embodiments, additional food ingredients are selected from the group consisting of sucrose, agave nectar, brown rice syrup, date sugar, honey, maple syrup, molasses, monk fruit, sugar alcohols, rare sugars, aspartame, sucralose, acesulfame potassium, and dietary fiber.

[0176] In some embodiments, the formulations described herein provide a sugar-like taste profile in which aftertaste or off-flavors (e.g., metallic or licorice flavor) are reduced, eliminated, or masked, or bitterness is reduced, eliminated, or masked, or residual sweetness is reduced, eliminated, or masked.

[0177] It should be noted that the modified MNEI protein according to the present invention may be produced by any method known in the art, for example, the protein may be produced synthetically by recombinant DNA technology, or by proteogenesis in microorganisms via fermenters, plants, plant callus, or other bioreactors. In some embodiments, the modified protein may be produced in bacteria, for example, E. coli. In some other embodiments, the modified protein may be produced in producing yeasts such as Saccharomyces cerevisiae or Pichia pastoris. In some other embodiments, the modified protein may be produced in filamentous fungi such as Trichoderma or Aspergillus.

[0178] The term "yeast and filamentous fungi" includes any Kluyveromyces sp., for example Kluyveromyces lactis, Kluyveromyces marxianus, Saccharomyces sp., for example Saccharomyces cerevisiae, Pichia sp., for example Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia memhranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pyperi, Pichia stiptis, Pichia methanolica, Hansenula polymorpha, Candida albicans, any Aspergillus sp., e.g. Aspergillus nidulans, Aspergillus Examples include, but are not limited to, niger, Aspergillus oryzae, Trichoderma reesei, Chrysosporium lucknowens e, Fusarium sp., Fusarium gramineum, Fusarium venenatum, Physcomitrella patens, Myceliopthora, and Neurospora crassa.

[0179] In some embodiments, the DNA sequence of a selected amino acid sequence is optimized at both the RNA and DNA levels. At the RNA level, this includes minimizing RNA secondary structures to ensure rapid insertion into ribosomes. At the DNA level, this includes codon optimization for the host organism (taking into account RNA-level optimization). Codon usage optimization prioritizes using the most abundant tRNA in the host organism for each amino acid expressed.

[0180] In relation to the above, it should be understood that, if provided, percentage values ​​such as 10%, 50%, 120%, and 500% are interchangeable with "multiple change" values, i.e., 0.1, 0.5, 1.2, and 5, respectively.

[0181] As used herein, all scientific and technical terms have their meanings as commonly used in the art unless otherwise specified. The definitions provided herein are for the purpose of facilitating the understanding of certain terms that are frequently used herein and are not intended to limit the scope of this disclosure.

[0182] As used herein, the term “about” means ±10%. “Comprises,” “comprising,” “includes,” “including,” “having,” and their conjugations mean “including, but not limited to.” The term “essentially from” means that the composition, method, or structure may include additional components, steps, and / or parts, but only if the additional components, steps, and / or parts do not substantially alter the basic and novel features of the claimed composition, method, or structure. As used herein, the term “about” indicates a value that may deviate from the value mentioned by up to 1%, more specifically 5%, more specifically 10%, more specifically 15%, and in some cases up to 20%, and the deviation range includes integer values, and where applicable, non-integer values ​​also constitute a continuous range.

[0183] When used in this specification and the appended claims, the singular forms "a," "an," and "the" should be noted as including plural nouns unless the context explicitly indicates otherwise.

[0184] As used herein, “solution” refers to a liquid mixture in which the secondary components (solute) are uniformly distributed within the primary components (solvent). In contrast to a suspension or a cloudy mixture, a solution is clear and free of particulate matter.

[0185] As used herein, “syrup” or “beverage syrup” refers to a beverage precursor to which a fluid, typically water, is added to form a ready-to-drink beverage or “beverage.” Typically, the volume ratio of syrup to water is 1:3 to 1:8, more typically 1:4 to 1:6. The volume ratio of syrup to water is also expressed as “throw.” A ratio of 1:5, which is commonly used in the beverage industry, is known as “1+5 throw.”

[0186] The formulation can be used "as is" or in combination with other sweeteners, flavorings, and food ingredients.

[0187] Non-exclusive examples of sweeteners include steviol glycosides, steviosides, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, dulcoside A, steviol bioside, rubusoside, and other steviol glycosides found in the Stevia Rebaudiana Bertoni plant, and mixtures thereof, stevia extract, Luo Han Guo extract, mogrosides, high-fructose corn syrup, corn syrup, invert sugar, fructooligosaccharides, inulin, inurooligosaccharides, coupling sugars, maltooligosaccharides, maltodextin, corn syrup solids, glucose, maltose, sucrose, lactose, aspartame, saccharin, sucralose, and sugar alcohols.

[0188] Non-exclusive examples of flavorings include cranberry, lemon, orange, banana, grape, pear, pineapple, guarana, apple, mango, bitter almond, cola, cinnamon, sugar, cotton candy, and vanilla flavoring.

[0189] Other non-exclusive examples of food ingredients include flavorings, acidulants, organic and amino acids, colorants, fillers, modified starches, gums, texturers, preservatives, antioxidants, emulsifiers, stabilizers, thickeners, and gelling agents.

[0190] As used herein, the terms “sugar-like characteristics,” “sugar-like taste,” “sugar-like sweetness,” “sugar-like,” and “sugar-like” are synonymous. Sugar-like characteristics include, but are not limited to, any characteristics similar to those of sucrose, such as maximum response, flavor profile, time profile, adaptation behavior, mouthfeel, concentration / response function behavior, taste and flavor / sweetness interactions, spatial pattern selectivity, and temperature effects. These characteristics represent the degree to which the taste of sucrose differs from the taste of natural and synthetic high-potency sweeteners. Whether a composition is more sugar-like is determined by an evaluation of sugar and functional taste-improving compositions by a sensory panel of experts. Such evaluations quantify the similarity in the characteristics of the composition. Preferred procedures for determining whether a composition has a more sugar-like taste are well known in the art.

[0191] As used herein, the terms “flavor” or “flavor characteristic” refer to the sensory perception of a combination of components of taste, smell, and / or texture. As used herein, the terms “enhance” include increasing, strengthening, emphasizing, expanding, and enhancing the sensory perception of a flavor characteristic without altering its nature. As used herein, the terms “modify” include changing, altering, suppressing, reducing, increasing, and supplementing the sensory perception of a flavor characteristic when its quality or duration is insufficient.

[0192] As used herein, "taste-modifying protein (TMP)" is defined as a protein that acts as a substitute for basic tastes, such as sweetness and umami, as well as a protein that has blockers, enhancers, masking agents, and flavor characteristics.

[0193] In this invention, "high-potency sweetener" refers to a protein that has a stronger sweetness compared to sucrose, and may be a naturally occurring protein, a recombinant protein, or a combination thereof. The high-potency sweetener exhibits a sweetness that is 5 times, 10 times, 50 times, 100 times, 500 times, 1000 times, 5000 times, 10000 times, 50000 times, 50000 times, or 100000 times sweeter than the same amount of sucrose.

[0194] As used herein, "nutritional functional components" refers to nutrients for humans and includes one or more selected from the group consisting of minerals, organic acids, vitamins, polyphenols, proteins, amino acids, dietary fiber, and carbohydrates (excluding sugars).

[0195] As used herein, the term “functional” refers to the preservation of a function (e.g., sweetness) after heat or other processes (although this may involve possible structural changes).

[0196] As used herein, the term “functional stability” refers to the stability of a formulation or consumer-packaged product under favorable conditions, and the stability that maintains functional sensory properties, rather than the chemical stability of the pure material in dry, aqueous, or buffered form.

[0197] As used herein, the term “foodstuffs” means any edible oral composition, including beverages, confectionery products, chewing gum products, or food products.

[0198] As used herein, the term “beverage” means any drinkable liquid or semi-liquid, including, for example, flavored water, soft drinks, fruit drinks, coffee-based drinks, tea-based drinks, juice-based drinks, milk-based drinks, jelly drinks, carbonated or still drinks, and alcoholic or non-alcoholic drinks.

[0199] As used herein, “orally ingestible composition” and “sweetening composition” are synonymous and refer to substances that come into contact with the mouth of a human or animal, including substances that are taken into the mouth and subsequently expelled from the mouth, and substances that are drunk, eaten, swallowed, or otherwise ingested, and are safe for human or animal consumption when used within generally acceptable limits. Examples of such compositions include foods, beverages, pharmaceuticals, functional foods, oral hygiene products / cosmetics, etc. Non-limiting examples of such products include non-carbonated and carbonated soft drinks such as cola, ginger ale, root beer, cider, and fruit-flavored soft drinks (e.g., lemon-lime, cranberry, or orange citrus-flavored soft drinks). Fruit juices containing fruit or vegetable-derived fruit juices, squeezed juices, fruit juices containing fruit particles, fruit beverages, fruit juice drinks, beverages containing fruit juice, beverages with fruit flavorings, vegetable juices, juices containing vegetables, and mixed juices containing fruits and vegetables, sports drinks, energy drinks, near water, and similar drinks (e.g., water with natural or synthetic flavorings), coffee, cocoa, tea, green tea, oolong tea and other teas or beverages, milk beverages, coffee containing milk components, café au lait, milk tea, fruit milk beverages, drinking yogurt, lactic acid bacteria beverages and other milk component-containing beverages, dairy products, baked goods, yogurt, jelly, gummy candies , desserts such as drinking jelly, pudding, bavarian cream, blancmange, cakes, brownies, mousse, and peanut butter, sweetened food or beverage products that can be eaten during tea time or after a meal, frozen foods, cold confectionery, such as ice cream, ice milk, lactose ice cream, etc. (food or beverage products made by adding sweeteners and various other types of ingredients to milk products, stirring the resulting mixture, and freezing it), and frozen desserts, such as sherbet and dessert ice cream, etc. (food or beverage products made by adding various other types of ingredients to sugar syrup, stirring the resulting mixture, and freezing it), ice cream, general confectionery, such as cakes, crackers, biscuits, baked goods such as bread filled with bean paste, or steamed confectionery,Rice cakes and snacks, table products, general confectionery, such as chewing gum (including compositions containing substantially water-insoluble chewable gum bases such as chicle or its substitutes (including rubber or certain edible natural synthetic resins or waxes)), hard candies, soft candies, mints, nougat candies, jelly beans, etc., sauces including fruit-flavored sauces and chocolate sauces, edible gels, creams including buttercream, wheat paste, and whipped cream, jams including strawberry jam and marmalade, breads including sweet breads or other starch products, spices, seasoned soy sauce used for grilled meat, yakitori, barbecue meat, etc., as well as general seasonings including tomato ketchup (ketchup), sauces, noodle soups, etc., processed agricultural products, livestock products, or processed meat products such as seafood and sausages, retort foods or beverage products, pickles, preserved foods, soy sauce, luxury goods, side dishes, potatoes Snacks such as chips and cookies, cereal products, drugs, quasi-drugs, and nutritional supplements (e.g., vitamins, cough syrups, throat lozenges, chewable tablets, amino acids, bitter drugs or medicines, acidulants, etc.) where the drug may be in solid, liquid, gel, or aerosol form, e.g., pills, tablets, sprays, capsules, syrups, drops, lozenges, powders, etc., drugs, quasi-drugs, and nutritional supplements, personal care products, e.g., oral compositions used in the mouth, e.g., mouthwashes, mouthwashes, toothpastes, tooth polishes, toothpastes, mouth sprays, teeth whitening agents, etc., nutritional supplements, animal feed, and functional products including any food or food component that may provide medical or health benefits, including the prevention and treatment of diseases (e.g., cardiovascular disease and high blood cholesterol levels, diabetes, osteoporosis, inflammation, or autoimmune disorders).

[0200] As used herein, stevia is the common name for Stevia rebaudiana (Bertoni), a perennial shrub of the Asteracae (Compositae) family native to Brazil and Paraguay. Stevia leaves, aqueous extracts of the leaves, and purified steviol glycosides isolated from stevia have been developed as desirable sweeteners, both as non-caloric and of natural origin. Examples of steviol glycosides isolated from Stevia rebaudiana include stevioside, rebaudioside A, rebaudioside C, dulcoside A, rubusoside, steviolbioside, rebaudioside B, rebaudioside D, and rebaudioside F.

[0201] Reb M (also known as rebaudioside X), (13-[(2-O-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]entcaul-16-ene19-euic acid-[(2-O-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-D-glucopyranosyl)ester] was isolated and characterized from Stevia rebaudiana.

[0202] As described herein, the food or beverage composition has improved food or beverage-related properties. The sweetness profile of the composition, including sweetness level, absence of off-flavors, reduced onset time, and reduced aftertaste, can be determined by any known taste test known in the art. For example, a comparison with the sweetness of sucrose or other sweeteners can be performed by a sensory panel, and the sweetness level can be graded as detailed in the following examples.

[0203] Non-limiting examples Example 1: Design of an MNEI-based protein The MNEI-based protein was designed as follows: Single-chain monellin, MNEI (SEQ ID NO: 45), is a polypeptide consisting of 96 amino acids with a molecular weight of approximately 11 kD and a pI of approximately 8.7.

[0204] Computer methods As described above, computer analysis and human-expert analysis provide a reduced sequence space that can be further analyzed computerically, by experts, experimentally, or in combination of these methods. Such analyses can be applied to individual amino acids, amino acid clusters, or other combinations.

[0205] During the Computational Protein Design (CPD) process, amino acid substitutions and / or deletions were permitted in certain regions less likely to be part of the receptor binding site, e.g., around the helix, the unexposed side of the beta-sheet forming the protein core, or in the manipulated loop that distinguishes MNEI from wild-type monellin. Rosetta runs yielded a 600K model. When the energy of all models was drawn, the resulting graph took the form of a logit function. The logit function (also known as the log-odds) is the logarithm of the odds p / (1-p), where p is the probability. This is the inverse of the sigmoid "logistic" function.

[0206] For further analysis, we selected the minimum 5K model. Plotting the number of substitutions (compared to MNEI) as a function of REU yielded a Gaussian distribution, indicating that the population is normal and suitable for further analysis.

[0207] Loop design in MNEI The Y47-K56 loop (i.e., the Gly-Phe peptide) in MNEI is a flexible loop, as demonstrated by molecular dynamics (MD) simulations at pH=2 and 7. This loop is not native to monellin and was introduced as a linker to two subunits (chain A and chain B) of native monellin. In this way, MNEI was produced. The introduced loop does not affect sweetness, and therefore MNEI has the same sweetness as monellin, but MNEI has a higher Tm (melting temperature), illustrating the potential effect the loop may have on protein stability (Curr Opin Struct Biol. 1999 Aug;9(4):494-9). Identifying the importance of the loop, the inventors redesigned and shortened the loop to increase yield, stability, and sensory profile.

[0208] procedure: Grafting Following the 3D structural alignment of the MNEI loop and two adjacent beta-sheets, two similar proteins were identified. Based on these PDBs, four models were constructed and minimized using rosettes.

[0209] Size-based and Ab-Initio Modeling Apart from the grafting procedure outlined above, additional loop modifications were obtained based on physical and biophysical considerations. To study the effect of loop length on MNEI stability, loops of various lengths were modeled using CPD software such as Rosetta or Swiss-PDB-Viewer. Loop modeling was performed based on physical considerations using the MNEI sequence or on homology modeling. Each model was then energy-minimized, and the energy was calculated using the GROMOS96 43B 1 force field. Based on this analysis, loops with 6, 5, and 4 residues were further tested because loops of these lengths were found to be more energetically preferable.

[0210] thermal stability Different variations of the MNEI sequence were constructed, and the energy of each model was predicted by rosette. For further analysis, the lowest energy sequence DM28 (having a 4-mer loop, i.e., a 4-amino acid loop shortened by 3 amino acids from the original MNEI loop) was selected, and energy CPD calculations were performed using a rosette with 100K repeats. Then, using DM28 as a template, additional variations were constructed by combining the 4-mer loop with specific amino acid substitutions (resulting in DM29, DM31, DM32, and DM33; see Tables 3 and 4). Based on DM09, one additional variant, DM30, was added. The lowest energy sequence DM31 was selected for further analysis.

[0211] [Table 1]

[0212] Figures 30-32 compare the properties of DM31 with those of MNEI, using crystal structures available in the PDB and those elucidated by the inventors. These figures suggest that the substitutions, insertions, and deletions resulting in the novel protein DM31, as well as the loop redesign, have made the protein more stable while possessing significantly more rigid structural elements. The increased stability is suggested by the compact, redesigned loop structure of DM31 compared to the loop structure of MNEI (Figure 30B). Furthermore, the B-factor analysis shown in Figures 31A and 31B demonstrates a reduced B-factor for loop residues of DM31 (Figure 31B), and a reduced mean for secondary structural elements (Figure 31A). Since B-factor exhibits irregularity, these results demonstrate the increased stability of DM31.

[0213] Figure 32 shows skeleton-mediated hydrogen bonding in a redesigned loop and adjacent beta chain, demonstrating better optimized hydrogen bonding compared to the corresponding loop in MNEI (Figure 32A, PDB ID: 2o9u), as well as novel bonding in this region of DM31 (Figure 32C). The novel hydrogen bonding exhibits a stable beta turn replacing the irregular loop. Hydrogen bonding is also shown in Table 1B. This figure illustrates 19 hydrogen bonds present in DM31 that are not present in at least one of the available MNEI structures. The numbers in the table indicate the distance between the involved hydrogen on the skeleton nitrogen and the skeleton oxygen as the acceptor. The table suggests that the 2o9u structure, the highest resolution structure available for MNEI (1.15 Å resolution), has fewer hydrogen bonds compared to the DM31 crystal structure (1.6 angstrom resolution), and that some of these bonds have not been optimized (in terms of distance and angle). Beyond the increase in factor B shown in Figure 31, the 2o9u structure has three residues with double occupancy (E4, M42, and E48), highlighting the irregularity in this high-resolution structure that is rigidified in the DM31 structure.

[0214] The inset in Figure 30A highlights the selected amino acid substitutions and the redesigned loop region. These changes underlie the increased stability and sweetness of the designer protein DM31. The inset showing the loop region in Figure 30A (also seen in Figure 30B) shows that residues in the loop area not only form novel hydrogen bonds (Figure 32) but are also involved in the elongation of two nearby beta chains, which also indicates increased stability. Overall, the replacement of the irregular loop with elongated beta chains linked by beta turns rigidifies this region of the protein, resulting in increased stability, as evidenced by the significant increase in melt temperature.

[0215] [Table 2]

[0216] Factor B (Debye-Waller factor) The Debye-Waller factor, also known as the temperature factor, B factor, or atomic displacement parameter, is included for all atoms in all X-ray structures deposited in the Protein Data Bank (PDB). These values ​​are given for all protein atoms and refer to the average displacement of the atom referenced from experimental electron density maps. Such disorder is a result of two distinct phenomena: dynamic disorder caused by temperature-dependent vibrations of atoms, and static disorder.

[0217] To demonstrate the stability of the remodeling loop, the skeletal B factor values ​​of the MNEI structure (PDB ID: 2O9U, 1IV7, 5Z1P) were compared to those of DM09 and DM31, based on crystal structures prepared by the Structural Proteomic Center (Weizmann Institute of Science). For each protein, the skeletal B factor values ​​were first normalized separately using Z-score normalization.

[0218] After normalization, the loop design introduced into DM31 (deletion of 3 amino acids) was found to reduce factor B in the redesigned loop by both removing positions with high levels of factor B and affecting adjacent residues.

[0219] Figures 31A and 31B demonstrate the normalized B factors of the MNEI structures, DM09, and DM31. First, the skeletal B factors were normalized separately for each structure using Z-score normalization, by region (A) and loop residue (B).

[0220] Crystal structure quality assurance analysis The MolProbity software pre-forms quality assurance analyses regarding the biophysical properties of protein structures. Using MolProbity, the MNEI structures were examined and compared to the crystal structures of DM09 and DM31. The comparison demonstrated that DM31 possessed favorable traits compared to the reference MNEI structures. It should be noted that DM31 does not have undesirable rotational isomers, and according to MolProbity, over 96% of its rotational isomers are favorable. Another aspect examined by MolProbity is the combination of skeletal dihedral angles related to the known statistical distribution of these angles for different amino acids. With respect to these distributions, DM31 exhibits favorable values ​​of over 97 percent, with no outlier angles.

[0221] [Table 3]

[0222] Hydrogen bonding: Introducing a beta turn into the loop region. Proteins are stabilized by hydrogen bonds, which also determine their secondary structure. Using PyMol, we analyzed the hydrogen bonding in the crystal structures of DM31, DM09, and a representative high-quality MNEI structure, PDB id 2O9U. This analysis revealed the presence of a novel hydrogen bond in the designer loop region between E48 and E51 (corresponding to E54 in MNEI). This introduced bond is the result of a design aimed at stabilizing the loop region, resulting in a conventional rigid type II beta-turn that is far more stable than the random coil unstable loops found in the MNEI structure.

[0223] Figures 32A to 32C demonstrate the hydrogen bonding of MNEI(A), DM09(B), and DM31(C). Loop regions are enclosed by rectangles.

[0224] Figure 33 shows that the DM31 loop structure corresponds to the structural definition of the beta-turn: the structure of the DM31 design loop, and the schematic beta-turn.

[0225] Example 2: Cloning, expression, and characterization of MNEI designer proteins DM13-DM33. Recombinant MNEI proteins were generated in E. coli BL21 (DE3+) under a T7 promoter induced with isopropyl β-D-1-thiogalactopyranoside (IPTG). Using this system, MNEI proteins were expressed as cytoplasmic proteins (soluble fraction) in a high-density fermentation process. Designer MNEI (DM) is a designed protein with up to 11% amino acid substitutions. Two DM molecules were disclosed to the inventors of this invention in International Publication No. 2019 / 215730 (DM08 and DM09). Both proteins contain three substitutions at positions 2, 23, and 65 of MNEI, resulting in higher thermal stability and increased stability.

[0226] The present invention discloses novel DM molecules generated to add up to three extra amino acid substitutions to either DM08 or DM09 at positions 35, 36, and 70, with or without reversing substitutions at positions 2 and 23. Furthermore, two unique DM molecules were generated by removing four amino acids from the loop connecting the monellin B and A chains (DM28 and DM29). Subsequently, three additional variants were generated by combining substitutions at positions 36 and 70 with the newly designed loop (DM31, DM32, and DM33). One additional variant was generated having only a single amino acid substitution for DM09 (DM30).

[0227] All DM was produced by E. coli fermentation and purified to a level of over 95%.

[0228] cloning Site-directed mutagenesis (SDM) based on the sequences of DM08 and DM09 was used to generate DM13 to DM33.

[0229] Loop removal in DM28-33 was performed using a similar deletion method. Table 2 lists the primers used in this process. All final construct sequences were verified.

[0230] [Table 4]

[0231] The nucleotide sequences of DM13-DM33 and DM-3, 8-12 are listed in Table 3.

[0232] [Table 5]

[0233] fermentation All DM clones were subjected to fermentation in 3L containers using the Sartorius BioStat B system or 2L containers using the Solaris Jupiter system. Some DM clones were produced by outsourcing to VTT (Finland) and SciVac (Israel). All fermentation followed the protocol based on "High cell-density fermentation of Escherichia coli" by Arie Geerlof-EMBL Hamburg 29 January 2008.

[0234] purification All DM samples were purified using the following steps. 1. Dissolution using a pressure homogenizer. 2. Protein capture on multimode resin, and elution at increasing NaCl concentrations in the same buffer. 3. At least one polishing step using resin from the following group: 1. Ion exchange. 2. Hydrophobic interactions. 3. Eliminate size. 4. Final microbial filtration (0.2 μm) and storage at -20°C.

[0235] Characterization Refinement level Purity levels were evaluated using gel electrophoresis, followed by Coomassi staining and concentration-based analysis. Concentration-based analysis was performed by running 20 pg / lane of each protein on a BSA standard curve with concentrations of 50–500 ng / lane. In all samples, the maximum contamination reached 3% (i.e., 97% purity).

[0236] Sweetness evaluation A professional sensory panel, including panelists initially calibrated with sugar solutions on a 0-100 scale (estimate of sweetness), where 0 = not sweet at all and 100 = very sweet. After calibration, tasters graded the test samples on the same scale according to a validated tasting protocol. A linear scale of sucrose was obtained at concentrations of 2°Bx, 4°Bx, 6°Bx, and 8°Bx. Brix (Bx) = gr / 100ml. Initial sweetness was evaluated in each test at a selected potency x4000 by comparing it with 6°Bx sugar, DM09, and a newly selected DM. All dilutions were performed with water only. The samples were evaluated by an expert panel at different occasions using 6°Bx sucrose and DM09 as controls (Figure 1).

[0237] DSF and DSC Analysis - Thermal Sensitivity Relative Tm was determined by differential scanning fluorescence (DSF) using Nanotemper Prometheus. DSF is an easy, rapid, and accurate method for analyzing protein stability and aggregation. DSF detects changes in fluorescence of tryptophan and tyrosine residues in proteins. The fluorescence of tryptophan and tyrosine residues is strongly dependent on their surrounding environment. Changes in protein conformation are reflected as changes in fluorescence. The inflection point is determined using the first derivative of the fluorescence ratio (330 / 350). Since a secondary reporter fluorophore is not required, protein solutions can be analyzed over a concentration range of 250 mg / ml to 10 μg / ml, regardless of the buffer composition. DM13-33 were analyzed at a concentration of 0.5 mg / ml in 10 mM phosphate buffer pH 7.

[0238] Table 4 summarizes the properties of the modified proteins DM13–DM33. The results show the roles of several amino acids in controlling protein sweetness and thermal stability. Substitution of leucine at position 70 with isoleucine, in addition to E2, E23, and Y65, increased Tm by 2°C. Stability was further increased by substituting lysine at position 36 with threonine, although this substitution also caused a decrease in protein sweetness. Loop designs resulting in a 4-amino acid loop resulted in increased stability, expressed as an increase in Tm of approximately 7–10°C.

[0239] [Table 6]

[0240] Conclusion: The influence of specific positions on Tm and sweetness levels Substitution with E2-N => Increase in Tm and sweetness (comparison between DM22 and DM23 or DM20 and DM21). Substitution with E23-A or V => Increase in Tm (comparison between DM13 and DM15 or DM17 and DM22). No clear effect on sweetness (against the background of other substitutions). E23-A is replaced with V => (comparison between DM09 and DM27). Replacement with E23 - I => Increase in Tm (comparison between DM13 and DM15 or DM17 and DM22). There is no clear effect on sweetness. Replacement with N35 - T => No clear effect on any parameter. Replacement with K36 - T => Increase in Tm, significant reduction in sweetness (comparison between DM14 and DM17, DM24 and DM14, or DM13 and DM16). Replacement of Y65 - R with K = : (comparison between DM08 and DM27) Replacement with L70 - I => Slight increase in Tm, no clear effect on sweetness (comparison between DM09 and DM14 or DM08 and DM13).

[0241] Loop design - deletion of E50, F52, R53 => Large increase in Tm, no clear effect on sweetness.

[0242] Example 3: Sensory evaluation of sweetness intensity and stability for monellin designer protein DM13 The dose - response of sweetness intensity of DM13 (Figure 2B), DM28 (Figure 2C), and DM31 (Figure 2D) was performed compared to MNEI (Figure 2A). Panelists were first calibrated with a sucrose solution on a scale of 0 - 100 (estimation of magnitude), where 0 = not at all sweet and 100 = very sweet. The linear scale of sucrose was obtained at concentrations of 2°Bx, 4°Bx, 6°Bx, and 8°Bx. Brix (Bx) = gr / 100ml. After calibration, tasters graded the test samples at increasing concentrations on the same scale according to a validated tasting protocol.

[0243] As demonstrated by Figure 2, DM13, DM28, and DM31 are 4 - fold sweeter than MNEI.

[0244] Heat treatment at 95°C for 30 seconds in citrate buffer Citrate buffer (pH=3) was preheated to 95°C in a thermomix. At 95°C, DM13 (at a concentration of 5°Bx isosweet) was added to the buffer solution and maintained at this temperature for 30 seconds. After 30 seconds, the solution was immediately cooled in a freezer.

[0245] A panel of experts (n=15) tasted the products and rated their sweetness intensity on a scale of 0 to 100. Each treated product was tasted in comparison to a reference (the same solution without heating). All products were provided with code numbers. As shown in Figure 4, DM13 is stable in citrate buffer at 95°C for 30 seconds.

[0246] Heat treatment in citrate buffer at 90°C for 10 minutes. Citrate buffer (pH 3) was preheated to 90°C using a thermomix. At 90°C, DM13 (at a concentration of 5°Bx isosweet) was added to the buffer solution, and the temperature was maintained at 1 minute, 3 minutes, and 10 minutes as appropriate.

[0247] After a suitable amount of time, the solution was immediately cooled in a freezer.

[0248] A panel of experts tasted the products and evaluated their sweetness intensity on a scale of 0 to 100. The treated products were tasted in comparison to a reference (the same solution without heating). All products were provided with code numbers. As shown in Figure 3, DM13 remained stable in citrate buffer at 90°C for 10 minutes.

[0249] DM13 sweetness stability after 8 weeks at 21°C and 32°C The shelf-life stability of DM13 was tested in citrate buffer (0.113% citric acid, 0.016% trisodium citrate, 99.9% water) at 21°C and 32°C for 4 weeks and 8 weeks. DM13 was added at a concentration of 5 Brix equivalents (potency 1:4000).

[0250] The treated products were tasted by a panel of experts and compared to the fresh solution. As shown in Figures 5A and 5B, DM13 remained stable for 8 weeks at both temperatures.

[0251] Example 4: Ketchup and plain yogurt formulation containing designer-MNEI(DM) protein Table 5 shows the ketchup formulations containing DM protein.

[0252] [Table 7]

[0253] Table 6 shows the formulations of yogurts containing DM protein.

[0254] [Table 8]

[0255] Testing Method - Expert Panel of Taste Proteins All sensory assessments were determined using a trained expert panel for analytical discrimination. The sensory expert panel was established through a screening process of potential tasters. Screening tests, conducted according to ISO standard (IS 8586-1), examined tasters' sensory sensitivity, consistency, and sensory memory. The panel was thoroughly trained and calibrated. Selected panels were regularly trained to maintain high performance results.

[0256] Sensory profiling of ketchup and plain yogurt prototypes - Test procedure: For each category (ketchup / plain yogurt), a panel of experts determined the sensory vocabulary. The vocabulary was constructed by tasting a wide range of products from each category and listing all relevant sensory attributes that describe the category. A diverse range of language was used to best describe the products.

[0257] After acquiring sensory vocabulary, select key attributes to be used to describe the product in the questionnaire.

[0258] Construction of sensory profiles for ketchup and plain yogurt: Panelists evaluated each test product against a reference product on a binary scale (-3 to +3) using a fixed reference point (0) across all attributes selected from the glossary. If the test product was evaluated as "more" than the reference product for a particular attribute (e.g., sweeter, thicker, etc.), a positive evaluation (+1, +2, or +3) was obtained, and if it was evaluated as "less" than the reference product for a particular attribute (e.g., not sweeter, not very thick, etc.), a negative evaluation (-1, -2, or -3) was obtained. Before and between attributes, the tasters were required to rinse their mouths with mineral water, eat unsalted crackers and cucumbers, and drink water again.

[0259] Results Ketchup prototype As demonstrated in Figure 6, the ketchup prototype with 69% less added sugar is less sweet, more sour, saltier, and has a stronger stinging sensation on the tongue compared to the ketchup prototype with DM09.

[0260] Figure 7 shows that the ketchup prototype with 69% less added sugar is less sweet, more sour, and has a lighter color compared to the full-sugar ketchup prototype.

[0261] It was demonstrated that the ketchup with DM09 (with 69% less added sugar) has a sensory profile very similar to the full-sugar ketchup prototype (Figure 8).

[0262] Figure 9 demonstrates that the ketchup with DM28 has a similar sensory profile compared to the ketchup with DM09, except that it has more "delayed" and more adhesiveness.

[0263] Figure 18 demonstrates that the ketchup with DM031 (with 69% less added sugar) has a sensory profile very similar to the ketchup with DM09.

[0264] After one month, the ketchup containing DM09 retains its sweetness. The changes observed in the product are typical of ketchup after one month (darker color, more flavored, more acidic, thicker, and less smooth texture) (Figure 10).

[0265] Yogurt prototype As demonstrated in Figure 11, plain yogurt with 33% less added sugar is less sweet than plain yogurt containing DM09 and with 33% less added sugar.

[0266] Figure 12 demonstrates that plain yogurt containing DM09 (with 33% less added sugar) has a sensory profile similar to that of the full-sugar yogurt prototype.

[0267] As shown in Figure 13, the strawberry yogurt containing DM28 has a similar sensory profile to the strawberry yogurt containing DM09, except that it is slightly more acidic.

[0268] Figure 19 demonstrates that strawberry yogurt containing DM31 has a similar sensory profile to strawberry yogurt containing DM09.

[0269] Figure 14 demonstrates that after a two-week shelf life, plain yogurt containing DM09 has a similar sensory profile to fresh plain yogurt containing DM09.

[0270] Example 5: Sweetener combinations Sensory profiles of sweeteners - Test procedure: Numerous sweeteners and sweetener combinations were screened. The best-performing sweetener combinations were stevia versus stevia + DM09, and monk fruit and stevia versus monk fruit, stevia, and DM09. Each sweetened solution had a final concentration equivalent to 5°Bx (in the two-sweetener combination, each sweetener was at a concentration equivalent to 2.5°Bx, and in the three-sweetener combination, each sweetener was at a concentration equivalent to 1.7°Bx).

[0271] The sensory attributes in the questionnaire were determined by preliminary tastings conducted by the panelists.

[0272] Construction of sensory profiles for each sweetener solution: Panelists evaluated each test solution (sweetener + DM09 / DM28) on a binary scale (-3 to +3) using a fixed baseline (0) across selected attributes, relative to a reference solution (sweetener without DM09 / DM28). A positive rating (+1, +2, or +3) was given if the test product was rated as "more" than the reference product for a specific attribute (e.g., sweeter, longer-lasting), and a negative rating (-1, -2, or -3) was given if it was rated as "less" than the reference product for a specific attribute (e.g., less-lasting).

[0273] Before and during the tasting, tasters were asked to rinse their mouths with mineral water, eat unsalted crackers and cucumber, and drink water again.

[0274] Lemon-flavored drink prototype Tables 7 and 8 show the formulations of lemon-flavored drinks containing DM protein.

[0275] [Table 9]

[0276] [Table 10]

[0277] result As shown in Figure 15, aqueous solutions containing stevia and DM09 are sweeter than aqueous solutions containing stevia alone at the same sweetness level equivalent. Figure 16 demonstrates that aqueous solutions containing the combination of monk fruit, stevia, and DM09 are sweeter and have a shorter "delayed onset" compared to aqueous solutions containing only monk fruit and stevia at the same sweetness level equivalent.

[0278] As shown in Figure 17, a lemon-flavored drink with 50% reduced added sugar (5°Bx equivalent) containing stevia has a very similar sensory profile to stevia and DM09 (2.5°Bx equivalent each).

[0279] Example 6: Chewing gum prototype containing designer monellin (DM) protein Chewing gum typically consists of a gum base, softeners, sweeteners, and flavorings. The gum base is what gives the gum its "chewiness." It is made from a combination of food-grade polymers, waxes, and softeners that give the gum the desired texture.

[0280] Table 9 shows the formulations of chewing gums containing DM protein.

[0281] [Table 11]

[0282] Preparation instructions: First, heat the gum base and put the melted mass into a blender.

[0283] Next, gradually add components 1-13 while continuing to mix.

[0284] Next, the mixture is kneaded to make the gum smooth, then formed and shaped.

[0285] A reference chewing gum sample containing sugar alcohols and artificial sweeteners is compared with a chewing gum sample containing the same amount of sugar alcohols and artificial sweeteners, to which sweetening proteins are added.

[0286] 0.01–0.05% by weight of sweetening protein was added to the recipe.

[0287] The sweet protein potency is 4000-8000, which corresponds to 48-56 Brix.

[0288] Sensory panel: A sensory profile of chewing gum was constructed using a trained panel of experts for analytical identification.

[0289] The panelists evaluated each chewing gum product tested across all attributes in the questionnaire. Attributes were measured at 30 seconds, 2 minutes, and 4 minutes.

[0290] Before and during the tasting, tasters were asked to rinse their mouths with mineral water, eat unsalted crackers and cucumber, and drink water again.

[0291] result As shown in Figure 20, chewing gum containing DM09 is sweeter than chewing gum without DM09 after 30 seconds of chewing.

[0292] Example 7: Peanut butter prototype with designer MNEI(DM) protein Table 10 shows the formulations of peanut butter containing DM protein.

[0293] [Table 12]

[0294] Mix all ingredients until the mixture is homogeneous.

[0295] result As shown in Figure 21, DM09, peanut butter with 50% reduced sugar, has a sensory profile very similar to that of full-sugar peanut butter.

[0296] Example 8: Iced coffee prototype with designer MNEI(DM) protein Table 11 shows the formulations of iced coffee containing DM protein.

[0297] [Table 13]

[0298] Mix coffee, sugar, maltodextrin, and DM09 to make a combined mixture. Then, mix 7-9g of the mixture with 89-94g of milk until the mixture is homogeneous.

[0299] result As shown in Figure 22, iced coffee with DM09 (70% sugar reduction) is sweeter than iced coffee without DM (70% sugar reduction).

[0300] Example 9: Cranberry Juice Prototype Tables 12 to 15 show the formulations of cranberry juices containing DM protein.

[0301] [Table 14]

[0302] [Table 15]

[0303] [Table 16]

[0304] [Table 17]

[0305] result Figure 23 demonstrates that cranberry juice (40% reduced sugar, stevia, and DM09) has a sweetness similar to that of full-sugar cranberry juice. Figure 24 demonstrates that cranberry juice with DM28 is sweeter than cranberry juice with DM09. Figure 25 demonstrates that cranberry juice (40% reduced sugar, stevia, and DM31) has a similar sensory profile to cranberry juice with 40% reduced sugar, stevia, and DM09.

[0306] Example 10: Dried cranberries and peach leather prototype Tables 16-18 show formulations of dried cranberries containing DM protein.

[0307] [Table 18]

[0308] The cranberries were immersed in infusion syrup at a 1:3 ratio for up to 6 hours until the cranberries reached 45-60°Bx (with full sugar) or 20-30°Bx (with DM), and then oven-dried at 70-120°C until the cranberries reached 70-86°Bx (with full sugar) or 33-45°Bx (with DM).

[0309] [Table 19]

[0310] The cranberries were immersed in infusion syrup at a ratio of 1:3 for up to 6 hours until they reached 45-60°Bx (when using full sugar) or 25-38°Bx (when using DM), and then the cranberries were oven-dried at 70-120°C until they reached 74-84°Bx (when using full sugar) or 42-54°Bx (when using DM).

[0311] [Table 20]

[0312] The cranberries were soaked in the infusion syrup in a 1:3 ratio for 2-6 hours until they reached 45-60°Bx (when using full sugar) or 20-30°Bx (when using DM). The cranberries were then oven-dried at 70-120°C. Drying was considered complete when the cranberries reached 70-86°Bx when using full sugar or 33-45°Bx when using DM. After 2 hours, the cranberries were removed from the oven and sprayed with the mixture (maltodextrin and dried DM09) (the amount of mixture sprayed was equivalent to 10% added sugar, calculated from the full sugar recipe). The cranberries were returned to the oven and further dried for another 10-30 minutes at 70-120°C.

[0313] Table 19 shows the composition of Momo leather containing DM09.

[0314] [Table 21]

[0315] The peaches were peeled and the pits removed. The peeled peaches were blended with citric acid in a food processor until smooth. DM09 was then added to the homogeneous blend. The mixture was poured, smoothed into a thin, uniform layer, and dried in a dehydrating oven at 40°C for 9-10 hours until dry. The dried peach leather was removed and allowed to cool. The leather was rolled up and stored in an airtight container.

[0316] result Figure 26 demonstrates that dried cranberries (50% reduced sugar and DM09) are sweeter than dried cranberries (50% reduced sugar).

[0317] Figure 27 demonstrates that Momo leather containing DM09 is sweeter than Momo leather without DM09.

[0318] Example 11: Iced green tea prototype with designer MNEI(DM) protein Table 20 shows the formulations of iced green tea containing DM protein.

[0319] [Table 22] * Full-sugar iced tea contains 8g / 100ml. ** Green tea extract is prepared by immersing a green tea bag in 95°C water for 1.5 minutes.

[0320] result As shown in Figure 28, iced green tea with 40% reduced added sugar + DM09 and stevia is sweeter than iced green tea with 40% reduced added sugar but without stevia.

[0321] Example 12: Maravi prototype with designer MNEI(DM) protein Table 21 shows the formulations of Maravi containing DM protein.

[0322] [Table 23]

[0323] Milk, cream, sugar, and rose water were heated to 100°C. Meanwhile, corn flour was mixed with the water. When the liquid reached 100°C, the corn flour was added and mixed. When the temperature dropped to 60°C, DM31 was added and mixed. The dessert was poured into serving dishes and cooled.

[0324] result As shown in Figure 29, Maravi with 50% reduced added sugar + DM31 is sweeter than Maravi with 50% reduced added sugar.

[0325] Example 13: In vitro digestibility study The purpose of the digestibility study was to determine the outcome of DM proteins used as sweeteners in the gastrointestinal tract after digestion. The protein tested was DM31 protein produced by microfermentation in Escherichia coli (E.Coli) BL21 (DE3).

[0326] An in vitro digestive static model was performed according to the INFOGEST protocol (Nature Protocols 14, 991-1014 (2019)).

[0327] In silico allergenicity analysis was performed on digested peptides obtained at the end of the digestion model.

[0328] The digestive cycle includes oral digestion (M), gastric digestion (G), and duodenal digestion (D). The digestive enzymes used were: gastric pepsin (prepared in simulated gastric fluid (SGF) - 2,000 U / ml SGF), and duodenal enzymes prepared in simulated duodenal fluid (SDF) - trypsin (100 U / mL SDF) and chymotrypsin (25 U / mL SDF). The positive control was a known fully digestible protein, α-lactalbumin. The negative control was the absence of any protein.

[0329] Sample analysis: Protein SDS gel - Protein samples from each digestion phase were electrophoresed on a 16.5% SDS PAGE tricine protein gel and stained with Coomassie blue.

[0330] Mass spectroscopy peptide identification: Two repeats of each cycle, G and D, were analyzed by LC-MS / MS using Q-Exactive Plus (Thermo) at the Smoller Proteomics Center, Technion, and DM was identified using Discover software and the host microorganism (E-coli) database for its sequence.

[0331] result As shown in Figure 34, the DM31 protein is partially digested at the end of the gastric phase and completely digested at the end of the duodenal phase. Results obtained by a static model using the INFOGEST protocol clearly demonstrate the digestibility of the DM protein during the physiological digestive process.

[0332] Peptides produced in the intestinal tract during DM-31 digestion do not pose an allergenic risk. The results demonstrate that DM-31 digestion is not associated with any safety concerns. [Sequence Listing Free Text]

[0333] Sequence ID 1: Composite sequence Sequence ID 2: Composite sequence Sequence ID 3: Synthesis Sequence ID 4: Synthesis Sequence ID 5: Synthesis Sequence ID 6: Synthesis Sequence ID 7: Synthesis Sequence ID 8: Synthesis Sequence ID 9: Synthesis Sequence ID 10: Synthesis Sequence ID 11: Synthesis Sequence ID 12: Synthesis Sequence ID 13: Synthesis Sequence ID 14: Synthesis Sequence ID 15: Synthesis Sequence ID 16: Synthesis Sequence ID 17: Synthesis Sequence ID 18: Synthesis Sequence ID 19: Synthesis Sequence ID 20: Synthesis Sequence ID 21: Synthesis Sequence ID 22: Synthesis Sequence ID 23: Synthesis Sequence ID 24: Synthesis Sequence ID 25: Synthesis Sequence ID 26: Synthesis Sequence ID 27: Synthesis Sequence ID 28: Synthesis Sequence ID 29: Synthesis Sequence ID 30: Synthesis Sequence ID 31: Synthesis Sequence ID 32: Synthesis Sequence ID 33: Synthesis Sequence ID 34: Synthesis Sequence ID 35: Synthesis Sequence ID 36: Synthesis Sequence ID 37: Synthesis Sequence ID 38: Synthesis Sequence ID 39: Synthesis Sequence ID 40: Synthesis Sequence ID 41: Synthesis Sequence ID 42: Synthesis Sequence ID 43: Synthesis Sequence ID 44: Synthesis Sequence ID 45: Synthesis Sequence ID 46: Synthesis Sequence ID 47: Synthesis Sequence ID 48: Synthesis Sequence ID 49: Synthesis Sequence ID 50: Synthesis Sequence ID 51: Synthesis Sequence ID 52: Synthesis

Claims

1. A modified single-chain monellin (MNEI) protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21, wherein the modified MNEI protein has improved thermal stability and increased sweetness compared to a reference MNEI protein having the amino acid sequence of SEQ ID NO:

45.

2. The modified MNEI protein according to claim 1, having a sweetness level increased by at least 1.5 times compared to the reference MNEI protein.

3. A product for human consumption comprising the modified MNEI protein according to claim 1 or 2 and an additional component for human consumption.

4. The product according to claim 3, wherein the component is (i) at least one of artificial flavorings, food additives, food dyes, preservatives, or sweeteners; (ii) selected from the group consisting of stevia, sucrose, agave nectar, brown rice syrup, date sugar, honey, maple syrup, molasses, monk fruit, sugar alcohol, rare sugar, aspartame, sucralose, acesulfame potassium, saccharin, neotame, advantame, fructose, glucose, steviol glycoside, and dietary fiber; (iii) synthetic or natural flavorings, food additives, food dyes, preservatives, fillers, or additional sugar additives; or (iv) salt.

5. (i) The product according to claim 3 or 4, wherein one or more modified MNEI proteins are present in an amount ranging from 0.2 mg to 30 mg per 100 g or 100 ml, and (ii) the pH is in the range of 2 to 8.

5.

6. The product according to any one of claims 3 to 5, wherein the product is a beverage or a food product, and (i) the beverage is selected from the group consisting of carbonated soft drinks, non-carbonated soft drinks, fountain beverages, frozen ready-to-drink beverages, coffee beverages, tea beverages, dairy beverages, fruit beverages, flavored water, fortified water, sports drinks, energy drinks, isotonic drinks, low-calorie drinks, and alcoholic beverages, and (ii) the food product is selected from the group consisting of bakery products, cookies, biscuits, baking mixes, cereals, confectionery, candies, toffee, chewing gum, bubble gum, dairy products, yogurt, flavored yogurt, peanut butter, soy sauce and other soy-based products, non-dairy products, salad dressings, ketchup, mayonnaise, vinegar, frozen desserts, meat products, fish products, bottled and canned foods, table sweeteners, chocolate, fruits, dried fruits, and vegetables.

7. The product according to claim 6, wherein (i) the carbonated soft drink is selected from the group consisting of cola, lemon-lime flavored sparkling beverage, orange-flavored sparkling beverage, grapefruit-flavored sparkling beverage, grape-flavored sparkling beverage, raspberry-flavored sparkling beverage, strawberry-flavored sparkling beverage, pineapple-flavored sparkling beverage, ginger ale, root beer, and malt beverage, and (ii) the non-carbonated soft drink is selected from the group consisting of fruit juice, fruit-flavored juice, juice drink, nectar, vegetable juice, vegetable-flavored juice, sports drink, energy drink, protein drink, vitamin-fortified water, near-water drink, coconut water, tea, coffee, cocoa drink, milk component-containing beverage, grain extract-containing beverage, and smoothie.

8. The product according to any one of claims 3 to 7, wherein the product is (i) a soft drink product with low or no added sugar, (ii) a dairy product with low or no added sugar, (iii) a sauce product with low or no added sugar, (iv) a dried fruit with low or no added sugar, (v) a gum product with low or no added sugar, (vi) a spread product with low or no added sugar, (vii) a syrup product with low or no added sugar, (viiii) a nutritional supplement product, (ix) a drug, or (x) product is a flavor modifier, flavor enhancer, or flavor masking agent.

9. A sweetening composition comprising the modified MNEI protein according to claim 1 or 2 and at least one additional sweetening enhancer, blocker, or modifier.

10. The sweetening composition according to claim 9, comprising (i) flavorings, food additives, food dyes, preservatives, and sweeteners; (ii) selected from the group consisting of stevia, sucrose, agave nectar, brown rice syrup, date sugar, honey, maple syrup, molasses, monk fruit, sugar alcohols, rare sugars, aspartame, sucralose, acesulfame potassium, saccharin, neotame, advantame, fructose, glucose, steviol glycoside, and dietary fiber; (iii) artificial or natural flavorings, food additives, food dyes, preservatives, fillers, or additional sugar additives; or (iv) at least one additional food component selected from the group consisting of salts.

11. A food or beverage composition comprising salt and (i) the modified MNEI protein according to claim 1 or 2, or (ii) the sweetening composition according to claim 9 or 10.

12. The food or beverage composition according to claim 11, which is at least one of a soft drink beverage or a sauce product.

Images